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Glial cells in Central Nervous System (CNS) were first studied during the 19th century by the 
eminent scientists as Santiago Ramon y Cajal, Pio del Rio-Hortega, and Rudolf Virchow. At 
that times, glia was merely described as a sort of “glue” necessary to maintain the structure 
of the nervous system: Rudolf Virchow, indeed, used the evocative German word 
“Nevernkitt”, literally meaning “nerve-glue” (Kettenmann and Verkhratsky, 2008). 
However, since Virchow’s observations, glia role in CNS has been widely reconsidered. 
From the concept of glia as a “substance… which lies between the proper nervous parts, 
holds them together and gives the whole its form in a greater or lesser degree” (Parpura, 
2012) new insights have been gathered and, to date, glia is considered more than a mere 
support for neural cells.  
Glial cell population is composed by 3 main cell types: astrocytes, microglia, 
oligodendrocytes and their precursors (NG2-glia).   
Astrocytes have a prominent role in neural development, in maintaining homeostasis and 
neurons survival, oligodendrocytes ensheath, and neuronal axons myelination, while 
microglia make up innate immune cells in the brain.  
 
ASTROCYTES: FUNCTIONS AND PHYSIOLOGICAL ROLES  
 
Among all the glial cell populations, astrocytes represent the most abundant component 
in adult brain (Kettenmann and Ransom, 2005). Given their importance, they are the best 




The eminent Italian scientist Camillo Golgi described astrocytes-like cells in 1872, even 
though the term “astrocyte” was first used by Michael von Lenhossek in 1893, evoked by 
the peculiar morphology of these cells ( the term astron means, indeed, star, while kytos 
stands for hollow vessel).  
It was thank to Ramon y Cajal’s impressive efforts that astrocytes complexity was finally 
comprehended: the development of a specific staining protocol targeting the astrocytic 
marker glial fibrillary acidic protein (GFAP), indeed, enabled Cajal to observe and describe 
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astrocytes pleomorphism (Ramon Y Cajal, 1909).   
During the last century, astrocytes were classified in two different groups, based on their 
morphological characteristics. Such classification is currently in use, so that nowadays we 
can distinguish between fibrous and protoplasmic astrocytes (Ramon Y Cajal, 1909).  
The former, mostly widespread in white matter, is characterized by small cell body 
endowed with numerous cytoplasmatic filaments and few thin processes. Fibrous 
astrocytes spatial disposition does not seem to follow any precise pattern: in fact, they 
appear equally distributed. On the other hand, protoplasmic astrocytes are the most 
common type of astrocytes within rodents and primate brains. Those cells are within the 
grey matter and seem characterized by a voluminous cell body with abundant granulous 
cytoplasm and numerous filaments (Ramon Y Cajal, 1909).  
Classical and more recent neuroanatomical studies showed that both subpopulations have 
extensive contacts with blood vessels. Furthermore, electronic microscopy analysis 
showed that protoplasmic astrocytic filaments can envelope synapses, while the fibrous 
ones have contacts with the nodes of Ranvier. However, both can form gap junctions at 
the level of the extremity of the close astrocytic processes (Peters et al., 1991).  
Through imaging experiments carried on post-mortem tissues, Oberheim and colleagues 
provided a high number of details on the morphology and structure of astrocytes, which 
showed high expression of glial fibrillary acid protein (GFAP), increasing according to an 
age-dependent pattern (Nichols et al., 1993).   
Astrocytes are characterized by the presence of thick fibrillar structures within body cell 
and processes, which are aggregation of thin glial filaments composed by GFAP. GFAP is 
included into the family of intermediate filaments as vimentin or nestin (Pekny and Pekna, 
2004) and its expression is narrowed down to astrocytes and Schwann cells. Many GFAP 
isoforms generated through alternative splicing pathway have been observed to date, for 
instance GFAP α, β, γ, δ, and κ, whose expression may vary in CNS due to physiological and 
pathological conditions.  
Observing the single astrocytic cells, it is clear that GFAP is not homogenously distributed 
in cytoplasm but rather mostly localized in main cell ramifications, while absent in cell body 
and thin cytoplasmic processes (Andreiuolo et al., 2009; Blechingberg et al., 2007; Roelofs 
et al., 2005).  
Thus, it is clear that GFAP expression represents the gold standard marker for astrocytes. 
Although other markers, for instance S100β, have been used, their selectivity has never 
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resulted highly accurate and thus they cannot represent a valid alternative to GFAP 
(Goncalves et al., 2008; Norenberg, 1979).  
Recent genetic analysis led scientists to the identification of a wide number of molecules 
with higher expression in rodent and human astrocytes in comparison with glial or 




Fig.1 Striatal astrocytes 
Immunofluorescence for GFAP on sagittal sections of adult rat striatum (20μm); image acquired 
under confocal microscope by Cervetto. The adult rat striatum was fixed for 24h at 4°C in 4% 
PAF, transferred in 30% sucrose solution in PSB and finally included in OCT before freezing in 
liquid nitrogen. The slices were saturated with blocking solution (containing Triton X-100 0.1% 
and 10% serum) for 1h at T° environment. The primary mouse anti-GFAP antibody (Sigma; 
diluted 1:500 in PBS with serum) was incubated for 24h at 4°C. After incubation with secondary 
antibody conjugated with Alexa Fluor 488, the slices were sealed with coverslip and a 20% 




2. Gap junctions 
 
Connexins are an important family of membrane proteins which can assemble each other 
to form six-subunits membrane pores, called connexon. Connexons, in turn, were observed 
to bind the homologous expressed on sorrounding cells in order to constitute channelswith 
the subsequent formation a direct line for metabolic and electrical signalling (LeBeau et al., 
2003; Herve et al., 2007; Yeager and Harris, 2007).   
Astrocytes are also physically connected each other through gap junctions. In details, 
channels are constituted of several connexon subunits (e.g: Cx30 and Cx43). Those 
channels mediate astrocytes-astrocytes communication enabling the exchange of 
important molecules as ions, metabolites, substrates (as glucose) and neuromodulators 
(Pannasch and Rouach, 2013). It is recognized that gap junctions play a key role in 
glutamate or potassium uptake, avoiding the potenitally harmful accumulation of those 
molecules in the extracellular space. This gap junctions-mediated communication pattern 
significantly supports the traditional signal transmission pathways, constituted by the 
neuronal synaptic network.  
 
3. Anatomical organization 
 
Astrocytic cells are characterized by a high number of processes which allow astrocytes to 
set up a well-structured network covering the whole CNS, enveloping neurons and nervous 
fibers and filling the anatomical spaces between these structures.  
Single cells observation showed that protoplasmic astrocytes in gray matter do not present 
overlapping domini and that only the distal extremities of the processes mutually interact 
through gap junctions (Bushong et al., 2002; Halassa et al., 2007; Nedergaard et al., 2003; 
Ogata and Kosaka, 2002). Between 5 to 10 thin cytoplasmatic processes extend from each 
protoplasmatic astrocyte spreading in the whole grey matter.   
According to diverse studies, a single astrocyte process can get in touch with hundreds of 
neurons dendrites and ensheath more than 100.000 synapses in cerebral cortex and 
hippocampus (Bushong et al., 2002; Halassa et al., 2007; Ogata and Kosaka, 2002).  
Interactions between synapses and astrocytic processes can go towards modifications: 
during memory development, for instance, astrocytic processes retract and synaptic space 




The important role of astrocytes in integrating information is structurally reflected in the 
tripartite synapses, where astrocytic processes tightly envelop synapses, contributing to 
regulate several aspects of synaptic signal transmission (Araque et al., 1999; Nedergaard 
and Verkhratsky, 2012; Perea et al., 2009; Verkhratsky and Nedergaard, 2014).  
It is noteworthy to point out that the number of synapses contacted by astrocytes varies 
according to the brain region and that not all synapses in CNS can be considered “private”, 
due to the presence of astrocytic processes.  
For instance, the 90% of synapses formed by climbing fibers in cerebellum are covered by 
astrocytic processes, as well as the 65% of synapses between parallel fibers and Purkinje 
cells (Grosche et al., 1999; Xu-Friedman et al., 2001)   
On the other hand, 29-56% of excitatory synapses in rat neocortex are ensheathed by 
astrocytic processes, while around the 90% of synapses within the IV cortical layer of adult 
mouse get in touch with the membranes of astrocytic perisynpatic processes (Bernardinelli 
et al., 2014).   
 
3. Physiology  
 
Unlike neurons, which generate action potential causing Ca2+-dependent neurotransmitter 
release, astrocytes have different excitation pathways, based on the action of ions and 
cytoplasmatic second messengers (Zorec et al., 2012). Astrocytes can perceive neuronal 
activity through their membrane receptors, which sense neurotransmitters in the 
extracellular space. Neurotransmitter as glutamate and purines can activate sodium and 
potassium channels or metabotropic G-protein coupled receptors (GPCRs, Agulhon et al., 
2008; Parpura and Verkhratsky, 2012; Zorec et al., 2012).  
The activation of astroglial receptor usually enhances ion-mediated signals and/or second 
messenger production (e.g: cAMP) (Na2+ o Ca2+; Kirischuk et al., 2012; Verkhratsky et al., 
2012). Variation of calcium and cAMP concentrations seem to have different timing: while 
Ca2+ increase is phasic, cAMP one is tonic (Horvat et al., 2016).  
The significant role of cytoplasmatic ions and second messenger in astrocyte-astrocyte and 
astrocyte-neuron communication was pointed out by several studies. In particular, the 
increase of intracytoplasmatic calcium can provoke gap junctions-mediated 
neurotransmitter release in astrocytes (Halassa et al., 2007; Nedergaard et al., 2003; Perea 
et al., 2009; Shigetomi et al., 2008; Volterra and Meldolesi, 2005).  
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The signalling pathways mediated by Gq and Gs can regulate exocytosis in astrocytes. 
Signalling molecules can in turn interact with neuronal receptors, modulating their 
excitability (Calegari et al., 1999; Parpura and Verkhratsky, 2012).  
 
4. Role of astrocytes in neuronal development 
 
During neurodevelopment, astrocytes differentiate later than neurons in several brain 
regions. However, astrocytes presence is determinant for the development and 
organization of both gray and white matter and for synaptogenesis. In particular, they can 
form molecular borders gradients which address neuronal axons and provide neuroblasts 
with the orientation during the migration towards their definitive site (Powell and Geller, 
1999). Astrocytes are also involved in the formation of future synapses through the release 
of several signal molecules as trombospondin (Barres, 2008; Christopherson et al., 2005; 
Ullian et al., 2001). They seem to be implied in the elimination of synapses through signals 
which induce the C1q complement expression in the synapses to be eliminated, thus 
evoking microglia response (Barres, 2008; Stevens et al., 2007).  
Finally, astrocytes are also implicated in the development of white matter, since it has been 
observed that loss or impairment of connexin and gap junctions lead to demyelination (Lutz 
et al., 2009).  
 
5. Blood-brain barrier and regulation of blood flow  
 
The blood brain barrier (BBB) is a physical barrier mainly composed by endothelial cells of 
capillaries, connected by tight junctions and forming a continuous barrier surrounding the 
blood vessels. BBB is interposed between blood and interstitial liquid and avoids to the 
potentially toxic molecules the access to cerebral parenchyma (Abbott et al., 2006; Ballabh 
et al., 2004).  
Endothelial cells in BBB are surrounded by a basal lamina, perivascular pericytes, and 
astrocytes endfeet: it was hypothesized that they are an important component of the BBB, 
regulating molecules transport from blood to the nervous tissue (Abbott et al., 2006; 
Ballabh et al., 2004; Beck et al., 1984; Savidge et al., 2007).  
Since astrocytes get in touch with blood vessels, they can regulate the blood flow to SNC 
through the release of molecular mediators as prostaglandin (PGE), nitric oxide, and 
arachidonic acid (AA) causing the modification of capillaries diameter and, subsequently, 
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of the blood flow (Gordon et al., 2007; Iadecola and Nedergaard, 2007). Furthermore, 
astrocytes might represent major mediators of blood flow variations in response to 
changes of neuronal activity (Koehler et al., 2009).  
 
6. Energy and metabolism  
 
Robust proofs suggest that astrocytes are major players in CNS metabolism. Astrocytic 
processes have contacts with blood vessels, axons (at the nodes of Ranvier level), and 
synapses, carrying glucose from the circulatory system to the cells within both gray and 
white matter.  
Interestingly, it is widely recognized that astrocytes represent a major glycogen storage in 
CNS and that this molecule is mainly concentrated in high-density synapses areas (Peter 
set al., 1991; Phelps, 1972).  
Recent studies showed that glycogen storage can support neuronal activity under 
hypoglycemic conditions and during periods of elevated neuronal activity (Brown and 
Ransom, 2007; Suh et al., 2007).   
Importantly, glycogen storage in astrocytes might be regulated by neurotransmitters, for 
instance glutamate, as well as by metabolites diffused through gap junctions (Brown and 
Ransom, 2007).  
 
7. Astrocytes heterogeneity 
 
Given the relevance of astrocytes in nervous system physiology, their variety and functional 
complexity, many studies aimed to further deepen our knowledge of specialization and 
heterogeneity of these cells (Hewett, 2009). An important astrocyte group presenting both 
similar and different characteristics in comparison with protoplasmic and fibrous 
astrocytes was observed and described many years ago. This population includes Muller 
glia in retina, Bergmann glia in cerebellum, pituitary cells in neurohypophysis. 
Those cells express typical astrocyte markers as GFAP, S100B, glutamine synthetase, and 
have specialized functions depending on the brain region of localization (Sofroniew and 
Vinters, 2010). Interestingly, heterogeneity of neuron-associated astrocytes is 
progressively increased during the evolutionary path, since astrocytes-neurons ratio raised 
is 1:6 in worms, 1:3 in rodent cortex, and 1:4 in human cortex, suggesting that their role  
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may have acquired higher importance through the evolution of nervous tissue (Nedergaard 




Nowadays, the idea according to whom astrocytes represent a secondary cell population 
in CNS has been overcome. Astrocytic cells are recognized as prominent cells in regulating 
the synaptic activity and brain plasticity (Araque et al, 1999).  
The release of transmitter was demonstrated first in neurons and only later in astrocytes. 
For many years, indeed, these cells were not considered able to secrete transmitters 
(Araque et al., 1999; Perea et al., 2009).  
 
1. Signals from neurons to astrocytes  
 
Astrocytes have different types of receptors for neurotransmitters, such as, for instance, 
glutamate and ATP. Several studies suggested that astrocyte processes in the cerebellum 
can be divided into different regions, each of which is able to interact with a limited number 
of synapses (Gundersen et al., 2015). These perisynaptic processes in Bergmann's glia are 
equipped with AMPA receptors for glutamate (Matsui et al., 2005; Saab et al., 2012) which 
can be directly activated by the glutamate released at the synapse level between parallel 
fibers and Purkinje cells (Matsui et al., 2005). The activation of receptors generates a local 
and transient increase of intracellular Ca2+ in the astrocyte processes of Bergmann's glia 
(Grosche et al., 1999). This communication seems to regulate the motor functions of the 
cerebellum (Saab et al., 2012).   
On the other hand, astrocytes of cerebral cortex do not express AMPA receptors: the 
hypothesis that glutamate NMDA receptors may transmit the synaptic signal to astrocytes 
was advanced (Lalo et al., 2006). Astrocytes in hippocampus respond to the release of 
neurotransmitters by activating metabotropic glutamate and ATP receptors, which in turn 
produce an increase of intracellular Ca2+ concentration (Dani et al., 1992; Pasti et al., 1997; 
Perea and Araque, 2005; Porter and McCarthy, 1996). Furthermore, it was demonstrated 
that also physiological sensory stimulation can generate similar increase of the intracellular 
Ca2+ levels in astrocytes in diverse CNS regions (Petzold et al., 2008; Schummers et al., 
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2008; Wang et al., 2006). It can be therefore supposed that astrocytes are strategically 
positioned to perceive at local level the synaptic activity of neurons and respond with an 
increase in intracellular Ca2+ (Gundersen et al., 2015).  
  
2. Signals from astrocytes 
 
The concept of astrocytes as secretory cells almost dates back to the discovery of glial cells: 
in 1895 Michael von Lenhossék introduced the term "astrocyte" (von Lenhossék, 1895), 
and in 1909 Hans Held observed granular inclusions in the astrocyte processes, interpreted 
as a sign of active secretion (Held et al., 1909). One year later, Jean Nageotte identified 
secretory granules in the glial cells of the grey substance (Nageotte, 1910). These granules 
were later called "gliosomes" by Alois Alzheimer and the hypothesis of an astroglial 
secretion was also considered by Wilder Penfield (Penfield et al., 1932). The term 
"gliosomes" coined in the first years of the 20th century should not be confused with the 
recent use of the name gliosomes to identify the sub-cellular particles derived from glial 
cells (Nakamura et al., 1993) and containing vesicles charged with transmitters (Stigliani et 
al., 2006; Cervetto et al., 2015; Cervetto et al., 2018). Both Nageotte and Penfield 
considered astrocytes as true endocrine components able to release their compounds into 
the bloodstream from pedicels closely associated with capillaries, or into extracellular 
space from the astrocyte processes surrounding synapses. In recent years, there was an 
increasing amount of evidence that astrocytes can release various substances that 
contribute to the regulation of CNS development and homeostasis, synaptogenesis and 
cognitive functions.  
Therefore, astrocytes can play an active role in the neuroglial secretory network, which, by 
analogy with the endocrine system, may be defined as the CNS gliocrine system (Vardjan 
and Parpura, 2015).  
Molecules released from astrocytes include: classical neurotransmitters (the 
"gliotransmitters", including glutamate, GABA, D-serine and ATP; Araque et al., 2014), 
precursors of neurotransmitter, neuromodulators, hormones, peptides, eicosanoids, 
metabolic substrates, reactive oxygen species scavengers (ROS), growth factors, factors 
that might be defined as "plastic" (e.g. substances that regulate synaptogenesis and 
synaptic connectivity), and finally pathologically relevant molecules such as inflammatory 
factors. Astrocytes release these signal molecules as a result of the increased intracellular 
Ca2+ in response to neuronal activity through numerous pathways. The same molecules are 
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usually released via different mechanisms, increasing the complexity/specificity of its 
action (Verkhratsky et al., 2016). Recently, many research groups focused on the study of 
the different release mechanisms used by astrocytes, ranging from exocytotic release to 
the use of channel proteins.  
 
2.1. Vesicular release of gliotransmitters  
 
Exocytotic release appeared very early during the evolution pattern (Spang et al., 2015; 
Vardjan et al., 2010) and most of the eukaryotic cells can release neurotransmitters. The 
fusion between the organuli and plasma membrane is fundamental both for intracellular 
communication and the activation of molecules, as receptors and transporters expressed 
in cell membrane. Exocytosis is dependent on the intracellular calcium levels and can occur 
both without stimulation (constitutive secretion) or in response to an exogenous 
stimulation (regulated secretion) (Kasai et al., 2012). Thanks to their fine regulation of 
neurotransmitters release, neurons represent the most reliable model for studying 
exocytotic neurotransmission. Exocytosis occurs also in astrocytes, even though through 
different molecular and kinetic mechanisms.  
Vesicular release is promoted by the SNARE proteins family (Sollner et al., 1993), which, 
concomitantly with an increase of intracellular Ca2+ concentration, assemble in a proteic 
complex that mediate the fusion process between vesicles and extracellular membrane, 
causing the release of the content within the extracellular space. Several astrocytes 
organuli are subjected to regulated exocytosis:  
 
- Synaptic-like microvesicles (SLMVs)  
 
SLMVs have small dimension (30-100 nm of diameter) and are present in astrocytes in 
groups of 2-15 vesicles (Bezzi et al., 2004; Jourdain et al., 2007; Bergersen et al., 2012; 
Martineau et al., 2013).  
Molecules are stored inside vesicles thanks to vesicular transporter for neurotransmitter 
(VNT), which present different substrate affinity and specificity in comparison with 
membrane transporters. To date, six types of transporters are known: the ones for 
glutamate (VGLUT 1-3), acetylcholine (VAChT), monoamine (VMAT1-2), GABA and glycine 
(VGAT) and, recently, ATP transporter (VNUT) (Chaudhry et al., 2008; Sawada et al., 2008; 
Blakely and Edwards, 2012).  
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D-serine storing in microvesicles is mediated by the VSerT transporter, although its 
molecular profile remains still unclear (Martineau et al., 2013)  
Transporter are essential molecules in chemical transmission and represent the marker for 
regulated exocytosis. Some transporters, for instance the VGLUT 1-3, have been identified 
in cultured astrocytes (Fremeau et al., 2002; Bezzi et al., 2004; Crippa et al., 2006; Kreft et 
al., 2004; Montana et al., 2006).  
In situ analysis on astrocytes via Gene Chip microarray or RT-PCR and 
immunohistochemistry lead to such variable and discordant results that transporters 
expression in astrocytes (and therefore the gliosis concept) was questioned.   
In particular, immunohistochemistry results from many research groups pointed out that 
VGLUT 1, VGLUT 2 andVGLUT 3 colocalize within thin astrocytic processes which ensheath 
synapses in CNS (Anlauf and Derouiche, 2005; Bezzi et al., 2004; BowserandKhakh, 2007; Li 
et al., 2013; Sahlender et al., 2014; Liu et al., 2011; Marchaland et al., 2008; Montana et 
al., 2004; Ni and Parpura, 2009; Potokar et al., 2009; Stenovec et al., 2007; Zhang et al., 
2004). However, Li et al. demosntrated that no expression of glutamate transporters in 
astrocytes can be detected by confocal imaging (Li et al., 2013). Such results were then 
confirmed by two other studies: microarray analysis never detected RNA transcripts 
codifying for VGLUT transporter in astrocytes from mouse brain (Cahoy et al., 2008; Lovatt 
et al., 2007), on the other hand, previous experiments carried out on isolated astrocytes 
showed the presence of mRNA for glutamate transporters (Bezzi et al., 2004; Danik et al., 
2005; Zhang et al., 2004).  
In astrocytes, both glutamate and D-serine are packed in SLMVs (Martineau et al., 2008, 
2013; Bergersen et al., 2012). In cultured astrocytes, SLMVs colocalize with D-serine 
(Mothet et al., 2005; Martineau et al., 2013) and with VGLUT transporters, suggesting that 
these molecules can be localized within the same organelle (Bezzi et al., 2004; Ormel et al., 
2012).   
Nevertheless, in situ studies showed that glutamate and D-Serine are packed in different 
vesicles within the same astrocytic cells (Bergersen et al., 2012). A comparative study 
between astrocytic microvesicles (Crippa et al., 2006; Martineau et al., 2013) and synaptic 
vesicles in neurons pointed out that the former contain D-serine and glutamate, while the 
latter glutamate, glycine and GABA but not D-Serine (Martineau et al., 2013; Sild and Van 
Horn, 2013). SLMVs are present in astrocytes from different cerebral regions, including 




Glutamate and D-serine release quantification from astrocytes was carried out mostly on 
cells in culture.   
An important number of studies share the same idea on the mechanisms underlying the 
vesicular release of these gliotransmitters (Bal-Price et al., 2002; Bezzi et al., 1998; Bezzi et 
al., 2004; Cali et al., 2014; Cali et al., 2008; Domercq et al., 2006; Görge et al., 2010; Höltje 
et al., 2008; Kanno and Nishizaki, 2012; Li uet al., 2011; Marchaland et al., 2008; Montana 
et al., 2004; Pasti et al., 2001; Trkov et al., 2012; Yaguchi and Nishizaki, 2010; Zhang et al., 
2004; Zhang et al., 2004). Two important aspects are pointed out in these works:  
1) glutamate and D-serine release are both Ca2+-dependent;  
2) that mechanism is sensitive to the inhibition of some components of the exocytotic 
release machine.  
In fact, VGLUT and pomp H+-ATPasi inhibitors or tetanic toxins inhibit the release of 
gliotransmitters in astrocytes (Bezzi et al, 2004; Mothet et al, 2005; Martineau et al, 2008, 
2014; Henneberger et al, 2010; Parpura and Zorec, 2010; Kang et al, 2013; Shigetomi et al, 
2013; Cervetto et al, 2015).   
Taken together, these results provide important proofs supporting the theory according to 
whom astrocytes use an exocytotic mechanism to release gliotransmitter in the 
extracellular environment. 
- Dense-core vesicles (DCVs)   
 
Dense-core vesicles play a key role in packaging and releasing hormones and 
neuropeptides in neuroendocrine (Burgoyne and Morgan, 2003) and neuronal cells 
(Klyachko and Jackson, 2002). DCVs can also store ATP, which is probably accumulated via 
the transporter VNUT, although its expression has never been confirmed. Ultrastructural 
characteristics of DCVs in astrocytes are similar to the ones in neuroendocrine and 
neuronal cells, even though their nucleus doesn’t appear as dense as the neuroendocrine 
cells one (Potokar et al., 2008). DCVs presence in astrocytes is limited in astrocytes: 
VAMP2-positive vesicles cover only the 2% of the total amount of vesicles (Crippa et al., 
2006); DCVs have in general greater dimension in comparison with microvesicles, 
presenting a diameter between 100 and 600 nm range (Calegari et al., 1999; Hur et al., 
2010; Prada et al., 2011), DCVs found in medium of cultured astrocytes are endowed with 
the secretory proteins secretogranine II (Calegari et al., 1999; Paco et al., 2009; Prada et 
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al., 2011) and secretogranine III (Paco et al., 2010), cromogranine (Hur et al., 2010), ANP 
(Kreft et al., 2004; Paco et al., 2009), neuropeptide Y (Ramamoorthy and Whim, 2008; 
Prada et al., 2011) and ATP (Coco et al., 2003; Pangrsic et al., 2007). Dense nuclei vesicles 
containing secretogranine were observed in astrocytes derived from human brain samples 
(Hur et al., 2010), confirming the existence of these vesicles in situ.   
 
-        Secretory lysosomes 
In vitro, lysosomes contribute to ATP packing and Ca2+-dependent exocytotic release 
(Zhang et al., 2007; Jaiswal et al., 2007; Li et al., 2008). Lysosomes dimensions are within 
the range of 300-500 nm and cohabit with microvesicles in astrocytes. Apparently, these 
organelles are not endowed with VGLUT transporter and VAMP2 (Zhang et al., 2007; Liu et 
al., 2011) protein, whilst specific lysosomes markers as catepsin D, LAMP1 (Zhang et al., 
2007; Martineau et al., 2008) and VAMP7 (Chaineau et al., 2009) are expressed. Exocytosis 
from lysosomes in astrocytes mostly depends on the protein VAMP7 which allows both 
ATP and catepsin β release.  
A negative regulation of VAMP7 expression inhibits the fusion of ATP-containing vesicles 
and the diffusion of ATP-mediated intracellular Ca2+ waves Verderio et al., 2012). Secretory 
lysosomes fusion is due to a slow and local increase of Calcium concentration, while 
microvesicles fusion is caused by Ca2+ peaks (Verderio et al., 2012).  
  
2.1.1. Molecular mechanisms of astroglial exocytotis  
 
Protein SNARE expression in cultured astrocytes was demonstrated 20 years ago (Parpura 
et al., 1995). Further studied stressed out that astrocytes also express proteins typical of 
neuronal synaptic vesicles, e.g. VAMP2, or involved in exocytotic trafficking of vesicles in 
non-neuronal cells as SCAMP and VAMP3 (Parpura et al., 1995; Maienschein et al., 1999; 
Wilhelm et al., 2004; Mothet et al., 2005; Crippa et al., 2006; Montana et al., 2006; 
Martineau et al., 2008). Interestingly, the expression of SNARE associated proteins as 
Synaptotagmine 4 has been demonstrated in vitro (Zhang et al., 2004a).  
Immunohistochemical and confocal microscopy studies showed that a considerable 
number of SNARE proteins, including VAMP2 (Wilhelm et al., 2004) and VAMP3 (Bezzi et 
al., 2004; Zhang et al., 2004a; Jourdain et al., 2007; Bergersen and Gundersen, 2009; 
Schubert et al., 2011) are expressed in situ, in addition to other SNARE proteins as TI-
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VAMP/VAMP7 (Verderio et al., 2012), SNAP 23 and sintaxin 1 (Schubert et al., 2011). VAMP 
2 and 3 colocalize with the transporters VGLUT1-2 on glutamate-carrying vesicles and, 
presumably, with D-serine; TI/VAMP7 colocalize with the markers of the late endosomial 
compartments (Verderio et al., 2012) loaded with ATP.  
On the other hand, neuronal proteins generally associated to SNARE proteins, such as 
synaptotagmine 1 and 2, and synaptophysin (Wilhelm et al., 2004), have not been detected 
in astrocytes in situ.  
In brain slices, VAMP2 and/or VAMP2 inhibition mediated by tetanus toxin abolishes 
glutamate (Jourdain et al., 2007; Perea and Araque, 2007) and probably D-Serine release 
(Henneberger et al., 2010) in astrocytes. Transgenic mice expressing a SNARE protein with 
negative dominant mutation in astrocytes (Pascual et al., 2005; Hines and Haydon, 2013) 
display abnormality in behaviour, in synaptic transmission and in neurons maturation 
(Pascual et al., 2005; Hines and Haydon, 2013; Nadjar et al., 2013; Turner et al., 2013; Lalo 
et al., 2014; Sultan et al., 2015). These data suggest that in vivo exocytosis is VAMP2-
dependent. 
 
2.1.2. Speed of exocytotis in astrocytes   
 
Although release in neurons occurs 0.5 ms after Ca2+ entry in cytosol, exocytotic release in 
astrocytes is a slower process, occurring later after stimulation (Neher, 2012; Sudhof, 
2012). 
Furthermore, inhibition of astroglial exocytosis affects only slow electrical activity in 
cerebral cortex (Fellin Lapchak and Taboada, 2010 et al., 2009), while the fast one is not 
apparently affected by alterations of gliotransmission (Slezak et al., 2012). The slow cynetic 
of vesicular release in astrocytes is likely related to the differences of the pathway 
underlying exocytosis in neurons and astrocytes. For instance, while active zones in 
presynaptic terminal are characterized by structurally patterned vesicle, electronic 
microscopy studies have never detected such a structure in astrocytes (Bezzi et al., 2004; 
Jourdain et al., 2007; Bergersen et al., 2012).   
Secondly, SNARE and SNARE-associated proteins responsible for neuronal and astrocytic 
exocytosis present differences in terms of the proteins SNARE complexes stability.  
Different isoforms of VAMP protein share similar properties and may participate in various 
SNARE complexes (Wilhelm et al., 2004; Montana et al., 2009). 
In astrocytes, protein VAMP2/3 or TI-VAMP, SNAP 23 and sintaxin are able to assemble to 
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compose the SNARE protein complex involved in vesicles fusion (Montana et al., 2009). 
In addition, R-SNARE protein associated with a single synaptic vesicle contains about 70 
molecules VAMP2 (Takamori et al., 2006), while 25 molecules were detected in a single 
astrocytic vesicle (Singh et al., 2014). That low presence of VAMP2 may lead to a reduction 
of the density of protein SNARE complex that might cause a delay during the process of 
vesicle fusion in astrocytes.  
 
2.2. Release of extracellular vesicles 
 
Extracellular vesicles can be divided in two main groups:  
- exosomes  
- ectosomes  
The latter generally transport a wide spectrum of bioactive substances such as cytokines, 
signalling proteins, mRNA and microRNA (Mause and Weber, 2010).  
Exosomes are definded as vesicles with a diameter variable between 40 and 100 nm and 
are generated from the fusion of multivesicular bodies (MVBs) with cell membrane 
(Mathivanan et al., 2010). 
On the contrary, ectosomes are larger (diameter from 100 and more 1000 nm) and are 
generated via cell membrane budding (Thery et al., 2009).   
Exosomes generation follows the endophytic pathway; during differentiation, MVBs go 
towards lipid enrichment as cholesterol and sphingomyelin (Kobayashi et al., 1998; 
Chevallier et al., 2008).   
Astrocytes can release both types of ECVs. In particular, ectosomes budding occurs upon 
activation of purinergic receptors P2X7 and involves fast activation of the acid 
sphingomyelinase which act on the outer layer of cell membrane. 
 
2.3. Non-vesicular release of gliotransmitters  
 
Gliotransmitters can be released by astrocytes not only through exocytosis-mediate 
mechanisms but also via non-vesicular pathway, as:  
a) release through opening of volume-regulated anionic channels,  
b) release through connexins (hemichannels) or pannexine  
c) diffusion through purinergic ionotropic P2X7 receptors  
d) release through transporters  
23 
 
e) release through molecules exchange via the cystine/glutamate antiporter (Malarkey and 
Parpura, 2011)  
f) release through K+-channels Trek-1 and bestrofina-1 channels (Best-1; Woo et al., 2012).
  
All the release pathways are mainly Ca2+-independent and apparently occur under 
pathological conditions (Agulhon et al., 2008; Hamilton and Attwell, 2010). The most 
common release mechanisms used by astrocytes depend on the opening of specific 
membrane proteins, as hemichannels and purinergic receptors P2X7.  
Hemichannels Cx43 opening enables glutamate (Jiang et al., 2011; Ye et al., 2003) and ATP 
(Arcuino et al., 2002; Cotrina et al., 1998; Kang et al., 2008; Stout et al., 2002) influx. 
According to some authors, P2X7 receptors might form a membrane pore which allows 
glutamate (Duan et al., 2003), ATP (Ballerini et al., 1996; Suadicani et al., 2006) and GABA 
(Wang et al., 2002) to pass through astrocytes membrane.   
Several studies tried to figure out the identity of the channel through which ATP is released: 
Saudicani and colleagues (2006) showed that ATP is released through P2X7 receptors and 
not hemichannels Cx43, while Kang (2008) and colleagues formulated diametrically 
opposed conclusions.  
Contreras and colleagues advanced the hypothesis that hemichannels maintain a close 
position during cell resting switching to an open conformation only after strong membrane 
depolarization (Contreras et al., 2003). Hemichannels, then, might represent an important 
tool for gliotransmission under pathological conditions. Interestingly, hemichannels and 
P2X7 receptors open conformation results to be not Ca2+-dependent (Thompson et al., 
2008; Ye et al., 2003) in contrast with the exocytotic pathway.   
In conclusion, it is likely that both hemichannels Cx43 and P2X7 receptors mediate a 
massive efflux of small cytoplasmatic molecules under physiological and pathological 
conditions. 
Several studies described pannexins, proteins constituting hemichannels and gap 
junctions, as involved in ATP release pathway (Iglesias et al., 2009; Suadicani et al., 2012).  
Garre and colleagues further suggested that pannexin and connexin-constituted 
hemichannels might enable ATP release from astrocytes upon ATP-mediated P2X7 
receptors activation (Garré et al., 2010).  
According to many studies in literature, also volume-regulated anion channels (VRAC) may 
play a role in astrocytic glutamate release in situ (Abdullaev et al., 2006; Haskew-Layton et 
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al., 2008; Kimelberg et al., 1990; 2006; Takano et al., 2005; Wang et al., 2013; Benfenati et 
al., 2009). VRAC-mediated glutamate release is regulated by intracellular Ca2+ level 
(Haskew-Layton et al., 2005; Mongin and Kimelberg, 2005). So far, this pattern release has 
been demonstrated in astrocytes under pathological conditions, for instance an ischemic 
stroke (Feustel et al., 2004; Zhang et al., 2008) or in spreading depression condition 
(Basarsky et al., 1999).  
It still remains unclear if neuronal activity is able to generate enough osmotic changes in 
astrocytes to cause VRAC opening and glutamate release.   
Furthermore, VRAC are not a selective way for glutamate release since many others amino 
acids, such as aspartic acid, taurine and glutamine, can be released through these channels 
(Kimelberg et al., 1990; Takano et al., 2005).  
In conclusion, it seems that physiological glutamate release can occurs in astrocytes 
through two pathways: channels or vesicular release.   
Further investigations will be warranted to figure out whether these two different 
pathways cooperate or not under physiological or pathological conditions (Gundersen et 
al., 2015).   
 
2.4. Gliotransmitters regulation of neuronal activity 
 
Synaptic activity and neuron plasticity can be modulated by the gliotransmitters released 
from astrocytes. For instance, experiments on slices of hippocampus showed that 
glutamate released from astrocytes can increase or inhibit neuronal activity (Andersson et 
al., 2007; Di Castro et al., 2011; Fiacco and McCarthy, 2004; Jourdain et al., 2007; Liu et al., 
2004; Navarrete et al., 2012; Navarrete et al., 2013; Perea G, Araque et al., 2007; Santello 
et al., 2011; Wang et al., 2013). Interestingly, Di Castro and colleagues demonstrated that 
astrocytes can perceive the reduction of neuronal basal activity responding with a rapid 
increase of the intracellular Ca2+ aimed to stimulate glutamate release and strength 
synaptic transmission (Di Castro et al., 2011).  
Astrocytes in somatosensorial cortex are able to regulate the activity of NMDA receptors 
and the A1 receptor causing, respectively, an increase and a decrease of cortical rhythm 
(Fellin et al., 2009).  
It is now recognized that astrocytes in hippocampus can release not only glutamate but 
also D-serine, which is thought to bind the glycine site on NMDA receptors, potentiating 
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the plasticity on glutamatergic synapses (Henneberger et al., 2010; Shigetomi et al., 2013; 
Yang et al., 2003)  
ATP is another gliotransmitter which can control neuronal activity (Koizumi et al., 2003). 
ATP can have different effects on cells, depending on the cerebral region where it is 
released. According to Pascal and colleagues, ATP released from astrocytes in hippocampus 
is rapidly converted in adenosine which, in turn, enhances the inhibition of synaptic activity 
through the activation of A1 receptors for adenosine (Pascual et al., 2005). Similarly, ATP 
gliotransmission is important for the homoeostatic processes underlying sleeping (Halassa 
et al., 2009).  
ATP can also activate postsynaptic P2X7 receptors causing a downregulation of GABAA 
receptors on dendrites (Lalo et al., 2014).  
Furthermore, increase of intracellular calcium level in astrocytes caused by variation of 
extracellular pH values have been reported. High calcium level causes the release of ATP in 
extracellular environment, which in turn activates chemoreceptors enhancing an increase 
of cellular respiration (Gourine et al., 2010).   
According to recent studies, single released gliotransmitter is able to generate a wide range 
of synaptic responses, likely related to the cerebral region where the release occurred. 
For instance, glutamate can enhance synaptic transmission through the activation of 
NMDA or metabotropic receptors on presynaptic nerve terminals (Fiacco and McCarthy, 
2004; Jourdain et al., 2007; Perea and Araque. 2007). Pathways underlying glutamate 
action seem to be very similar to the ones of inhibitory synapses, potentiating GABAergic 
inhibitory power (Kang et al., 1998). In addition, can also bind to NMDA receptors 
expressed on postsynaptic dendrites increasing, thus, neuronal excitability (Angulo et al., 
2004; Fellin et al., 2004; Perea and Araque, 2005). Notably, although the activation of 
astrocytic receptors leads to intracellular Ca2+ signalling not all of them can trigger 
gliotransmitter release. Volterra and colleagues hypothesized that local intracellular Ca2+ 
concentration variations in ensheathing-synapses astrocytic processes can control 
gliotransmission and consequently its effects on synaptic activity (Volterra et al., 2014). 
Since the effects of the released gliotransmitter are strictly related to the kind of neuronal 
receptor that will be bound, neurons-astrocytes communication scenario appears very 
complex. For instance, glutamate has a neuro-protective effects when binding synaptic 
NMDA receptors, whereas it enhances increase of NO and consequent neuronal damaging 




Notably, astrocytes heterogeneity can contribute to explain different molecular pathways 
underlying gliotransmitter release. In fact, it is recognized that grey matter astrocytes from 
different cerebral regions show different morphology and, therefore, a different molecular 
composition (Emsley and Macklis, 2006). 
2.4.1. L-lactate 
 
The idea that lactate, generated from cerebral metabolism, can work as a gliotransmitter 
was recently formulated. Astrocytes, indeed, can produce and release not “classical” 
transmitters such as lactic acid, probably released via the so called “volume transmission” 
in CNS (Bergersen and Gjedde, 2012). Astrocytes synthesize lactate via glycolysis or from 
glucose from blood stream. Lactate can diffuse following a concentration gradient:  
1) in the intracellular environment  
2) through gap junctions in astrocytes  
3) in the extracellular space through transporters for monocarbossilic acid (MCT)  
4) in extracellular space   
5) in proximal neurons and in other cellular types through MCT (Gundersen et al., 2015). 
Lactate released from astrocytes through the mechanisms listed above might be an 
autocrine mediator for astrocytes or, alternatively, as a paracrine mediator for neurons 
sited in other regions than astrocytes.  
Lactate in nervous tissue, indeed, can diffuse for long distances.  
During acid lactic synthesis from piruvate NAD+ is generated, which is fundamental for 
glycolysis. MCT transporter co-transport lactate in exchange with protons, a process 
enhanced by the concentration gradient generated from the production of lactate 
(Mookerjee et al., 2015). The variation of pH value due to this reaction can determine 
effects on a wide range of receptor and ionic channels (Wemmie, 2011), including 
glutamate receptors (Makani and Chesler, 2007; Traynelis and Cull-Candy, 1991). Changes 
of pH values can also affect histones acetylation influencing, therefore, gene expression 
(McBrian et al., 2013). Thus lactate, increasing the NADH/NAD+ ratio, can influence the 
activity of NMDA receptors, increasing also the activity of NMDA receptors and intracellular 
levels of calcium, stimulating the expression of genes involved in synaptic plasticity both in 
vitro and in vivo (Yang et al., 2014).  
The G-protein coupled receptors GPR81, receptor for lactate, was found in brain some 
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years ago (Bergersen et al., 2012; Bozzo et al., 2013; Lauritzen et al., 2014).   
However, the role of lactate in brain remains not still clear. Some studies on rodents 
pointed out that lactate is able to inhibit neuronal activity. For instance, lactate receptor in 
rat hippocampus slices inhibits forskolin-induced cAMP production (Lauritzen et al., 2013), 
while in primary culture of mice cortical cells can inhibits the activity of neurons, including 
the Gabaergic ones (Bozzo et al., 2013). According to these studies, after being released 
from astrocytes following adrenergic stimulation, lactate activate HCAR1 receptor on 
neurons (Gundersen et al., 2015).  
On the other hand, other studies supported a role of lactate as a positive modulator of 
norepinephrine release from neurons in locus coeruleus: lactate synthesized from 
astrocytes provoke, indeed, cAMP up-regulation in these neurons (Tang et al., 2014). 
Notably, only astrocytes in CNS contain a large quantity of glycogen, clearly representing a 
source of lactate. According to the astrocyte-to-neuron lactate shuttle hypothesis (ANLS), 
lactic acid produced during glycolysis (Peters et al., 1991) is carried both outside and inside 
active neurons (Pellerin and Magistretti, 2012).   
Neuronal synaptic transmission (Nagase et al., 2014) and memory formation (Suzuki et al., 
2011) seem to be lactate-dependent mechanisms. The role of lactate in synaptic plasticity 
is further supported by Robinet and Pellerin, who observed that the Brain-derived 
neurotrophic factor (BDNF) increases the expression of both the lactate transporter MCT2 
and postsynaptic proteins (Robinet and Pellerin, 2011). Astrocytes can rapidly uptake and 
release lactate due to the gap junctions, they can also carry glucose towards neurons 
(Gandhi et al., 2009).   
Astrocytic thin processes completely lack mitochondria but use their glycogen reservoir or 
containing-phosphate high energy compounds as energy source. Glycogenolisis and 
glycolysis in astrocytic processes lead to intra and extracellular increase of lactate 
concentration (through MCT transporter) (Lavialle et al., 2011).  
It was reported that Purkinje cells after AMPA receptor activation were able to produce 
lactic acid from environmental glucose. The activation of these neurons leads to higher 
levels of extracellular lactate, postsynaptic currents, blood flow, and glucose and oxygen 
consumption (Caesar et al., 2008). These effects are inhibited by CNQX, AMPA receptor 
antagonist, with no inhibition of glycogenolisis (Caesar et al., 2008).  
In synthesis: lactate released from excitatory synapses or astrocytic processes through 
volume transmission might be able to activate HCAR2 receptor, and probably other lactate 
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receptors, expressed on neurons.  
The selective localization of lactate transporter MCT2 (Bergersen et al., 2005) and receptor 
HCAR1 (Lauritzen et al., 2014) on neuronal postsynaptic membrane, and in the intracellular 
compartment of glutamatergic dendritic spines, stress the role of lactate as a point of union 
between synaptic and neuroglial transmission (Gundersen et al., 2015).  
 
ASTROCYTES: PATHOLOGICAL ROLES 
 
In general, pathologies (including neurologic diseases) can be defined as the homeostatic 
imbalance of a tissue, an organ or a system. Despite neuropathologies have been 
considered for decade exclusively linked to the neuronal cells, this neurocentric vision has 
been recently questioned. Nowadays, indeed, glial cells, and in particular astrocytes, are 
considered important players in neuropathology. According to this “astrocentric” vision, 
astrocytes are the major responsibles for nervous tissues homeostasis and actively 
contribute to its protection under pathological conditions (Burda and Sofroniew, 2014; 
Giaume et al., 2007; Nedergaard et al., 2010; Parpura et al., 2012; Sofroniew, 2009).   
Astrocytes display a wide range and regionally specialized functions (Anderson et al., 2014; 
Chaboub and Deneen, 2012; Matyash and Kettenmann, 2010; Oberheim et al., 2012; 
Parpura et al., 2012; Schitine et al., 2015). For instance, they divide parenchima within grey 
substance in relatively independent units, known as neurovascular units, characterized by 
the presence of both neuronal and vascular elements (Bushong et al., 2002; Iadecola and 
Nedergaard, 2007; Nedergaard et al., 2003). All cells of nervous tissues are involved in CNS 
cellular pathophysiology: since the multitude of their functions, astrocytes can be involved 
in all the neuropathological conditions (Burda and Sofroniew, 2014). Being able to 
synthesize and store glycogen, astrocytes maintain CNS homeostasis. Regardless its 
aetiology, nervous tissues damaging can compromise CNS homeostasis: through molecular 
mechanisms, astrocytes can protect neurons from glutamate toxicity, extracellular K+ and 
ROS action. Furthermore, astrocytic cells provide to under stress neurons energetic 
substrates. 
Loss of these delicate functions can trigger the progression of diverse pathologies, such as 
ALS and encephalopathies (Verkhratsky et al., 2014a, 2016). Many changes at astrocytic 
levels could coexists or emerge during the progression of neurological pathology. A 
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classification of astrogliopathology based on functional responses of astrocytic cells has 
been proposed:  
1) astrocitopathies, characterized by astroglial atrophy or pathological modelling 
2) reactive astrogliosis (Pekny et al., 2016). 
1) Many neurological pathologies have been associated to astrocytes degeneration, 
atrophy or functional asthenia. The “gliodegeneration” concept was introduced for the first 
time by Emilie Croisier and Manuel Graeber in 1996 (Croisier and Graeber, 2006). 
Astroglial atrophy is generally characterized by loss of function and was described in 
diverse pathologies, including also psychiatric and neurodegenerative disorders (Hazell, 
2009; Rajkowska and Stockmeier, 2013; Rossi et al., 2008; Verkhratsky et al., 2014a, 
2014d). Atrophy causes depletion of both neuroprotection and synapses ensheathed by 
astrocytic processes, with a subsequent decrease of homoeostasis. Such a condition 
commonly leads to glutamate uptake impairment which in turn disrupts neurotransmission 
and promotes excitotoxicity. Astrocytes asthenia might also go towards to the failing of 
active astrogliosis, worsening the neuropathology outcome (Verkhratsky et al., 2014b).  
 
2) Astrocytes can enhance a specific defensive response, defined as reactive astrogliosis. 
Transcriptomic analysis on reactive astrocytes after treatment with two different stimuli, 
ischemic ictus or bacterial LPS, showed differences, pointing out that stress signals may 
draw molecular characteristics of astrogliosis process (Zamanian et al., 2012). Astrogliosis 
represents a crucial component of cell pathophysiology and its suppression usually leads 
to a worsening of neuronal damages avoiding tissue regeneration (Sofroniew and Vinters, 
2010).   
 
1. Reactive astrogliosis 
 
Astrogliosis is widely used as a characteristic marker of CNS pathology. Basing on 
experiments on murine models, a new definition of reactive astrogliosis has been recently 
proposed. Four key characteristics are included (Sofroniew, 2009): 
1) Reactive astrogliosis is a range of potential molecular, cellular and functional modifications 




2) Modifications whom astrocytes are subjected to are related to severity of damage along 
with a gradual but continuous alteration of molecular expression, a progressive cellular 
ipertrophy, and cells proliferation with subsequent scar onset; 
3) Modification occurring during astrogliosis are regulated by intra and intercellular signals; 
4)  Such changes can affect astrocytic activity both through gain or loss of functions which can 
positively and negatively affect neuronal and non-neuronal cells.  
 
1.1. Mild or moderate astrogliosis 
 
The pathological background is characterized by up-regulation of genes such as GFAP 
(Sofroniew, 2009) and by atrophy of both astrocytes cell body and processes (Wilhelmsson 
et al., 2006). Mild or moderate astrogliosis is generally due to non-blunt trauma or 
activation of the innate immune system. When the main cause of astrogliosis is eliminated, 
astrocytes can assume again a similar phenotype to the one of normal tissue (Sofroniew, 
2009).  
 
1.2. Severe diffuse astrogliosis  
 
Such pathological condition is characterized by high GFAP and other genes up-regulation 
and by considerable cell body and processes hypertrophy. Astrocytic proliferation leading 
to an extension of cytoplasmic processes was observed (Sofroniew and Vinters, 2010). This 
causes an overlapping of processes of neighboring astrocytes with a subsequent long-term 
reorganization of nervous tissue architecture.  
 
1.3. Scar-forming astrogliosis 
 
In addition to the molecular and structural modifications previously described, astrogliosis 
can lead to the disruption of healing processes, promoting the formation of scars 
surrounding the lesion. Recent evidences demonstrated that such scar onset emergence 
typically occur at the edges of important tissues damage, necrosis, infection or 
inflammatory autoimmune infiltration and represent a defensive barrier against 
inflammatory cells and infective agents (Bush et al., 1999; Drogemuller et al., 2008; 
Faulkner et al., 2004; Herrmann et al., 2008; Sofroniew, 2009; Voskuhl et al., 2009).  
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On one hand, lesion isolation promotes a clinic stabilization and patient survival, on the 
other hand it might negatively affect the regeneration mechanisms occurring during the 
subsequent stages (Silver and Miller, 2004).  
Interaction between reactive astrocytes with other cells, mostly fibroblasts and meninges, 
is an important characteristic of glial scars. Furthermore, a dense extracellular matrix 
mostly composed of collagen and containing diverse molecular signals inhibiting axonal 
and cellular migration is synthesized.  
The role of glial scars in inhibiting axonal regeneration has been well known since scars 
were first described 100 years ago. For this reason, they have been merely considered as 
an obstacle for functional recovery of the damaged cerebral region (Ramon y Cajal, 1928). 
However, the negative role of astrogliosis has been questioned by experiments on 
transgenic models. 
Recent results shed a new light on the protective role of reactive astrocytes through 
different pathways:  
-  glutamate uptake (Bush et al., 1999; Rothstein et al., 1996; Swanson et al., 2004); 
- protection from NH4+-mediated toxicity and oxidative stress (Che net al., 2001; Shih et 
al., 2003; Swanson et al., 2004; Vargas et al., 2008);  
- Neuroprotection through adenosine release and β-amiloid degradation (Che net al., 
2001; Shih et al., 2003; Swanson et al., 2004; Vargas et al., 2008)  
- Enhancing BBB recovery (Bush et al., 1999); 
- Reduction of vasogenic edema after trauma, storke or obstructive hydrocephalus (Bush 
et al., 1999; Zador et al., 2009); 
- Extracellular liquid stabilization and ions balancing (Zador et al., 2009); 
- Limitation of diffusion of inflammatory cells or infective agents from damaged area or 
healthy parenchima (Bush et al., 1999; Drogemuller et al., 2008; Faulkner et al., 2004; 
Herrmann et al., 2008; Li et al., 2008; Myer et al., 2006; Okada et al., 2006; Voskuhl et al., 
2009). 
Several researches demonstrated that astrogliosis is not an all-or-none mechanism due to 
an on/off regulation, but a finely regulated process environment-dependent and regulated 
by a multitude of specific molecular signals mediating specific responses (Sofroniew, 2009; 
Sofroniew and Vinters, 2010).  
Numerous molecules can trigger astrogliosis processes or regulate its specific aspects: 
- Growth factors and cytokines, as IL6, TNFa, INFy, IL1, IL10, TGFb, FGF2 
32 
 
- Innate immunity mediator as lipopolysaccharide (LPS) and other tool-like receptors 
ligands 
- Neurotransmitter as glutamate and noradrenaline 
- Purines, e.g. ATP 
- ROS, e.g. NO 
- Glucose depletion and subsequent hypoxia 
- Metabolite related to neurodegeneration as B-amiloid 
- Molecules associated to systemic metabolic toxicity, as NH4+ 
- Regulator of cell proliferation as endothelin-1 (Sofroniew, 2009).  
In addition, many microRNA (miR), e.g. miR-21 and miR-181, and some miR-regulatory 
enzimes as Dicer able to modulate astrogliosis and its functions, have been indentified: 
such results indicate therefore the existence of a further level of astrogliosis regulation 
(Bhalala et al., 2012; Hutchison et al., 2013). All CNS cells can release molecular mediators 
of astrogliosis in response to nervous tissue damages (Sofroniew, 2009).   
It is increasingly recognized that molecular, morphologic and functional changes in reactive 
astrocytes are finely regulated by inter and intracellular signals which reflect the context 
of the specific stimulus and generate an astrogliosis-mediated response (Sofroniew, 2009). 
Furthermore, reactive astrocytes can in turn produce and release numerous types of pro- 
and anti-inflammatory factors in response to different kind of stimuli (Eddleston and 
Mucke, 1993; John et al., 2003) and can exert pro- or anti-inflammatory effects on microglia 
(Farina et al., 2007; Min et al., 2006). Thus, astrocytes are able to produce a wide range of 
effects depending on damage etiology and cerebral region where the damage occurred, 
under control of specific molecular pathways (Sofroniew, 2009).  
 
1.4. Alexander Disease 
 
Alexander disease (AxD) is one of the clearest examples of primary astrocytes pathology. 
AxD is a rare genetic neurodegenerative disorder, caused by a gain-of-function mutation 
of the GFAP gene (Brenner et al., 2009; Messing et al., 2012). Mutated GFAP, along with 
other constitutive proteins, form protein aggregates within astrocytes, called Rosenthal 
fibres, a distinctive marker of Alexander diseases (Herndon et al., 1970; Iwaki et al., 1989). 
One of the major modification observed in affected astrocytes is the decrease of 
membrane glutamate transporter expression. In particular, immunohistochemistry studies 
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showed a reduction of 75% of EAAT2 in AxD murine models, while a complete or variable 
EAAT2 depletion was observed in the hippocampus of patients affected by AxD (Tian et al., 
2010).  
Reduction of astrocytic glutamate uptake causes a risk of glutamate overload in neurons 
and, thus, the risk of excitotoxicity, that might explain why seizure is common in AxD 
patients (Messing et al., 2012).  
  
1.5. Neuronal lesions 
 
Traumatic lesions occurring in brain and spinal cord can have different forms (e.g. wounds 
or concussions), dimension (focal or diffuse), severity and anatomical localization 
(Verkhratsky et al., 2016). However, reactive astrogliosis is the major CNS response to 
nervous tissue damage, even though the phenotypes of activated glial cells appear highly 
heterogeneous according to the pathological context (Burda et al., 2015). Astrocytes 
responses, indeed, are affected by the distance and severity of the lesion.   
The activation of the molecular processes leading to astrogliosis probably involves a 
massive release of ATP from injured cells, causing a subsequent generation of InsP3-
mediated Ca2+ signalling in astrocytes (Huang et al., 2012; Roth et al., 2014)  
Astrocytes limit injuries caused by focal traumas through the formation of glial scars, which 
generate a barrier surrounding the injured area. Astrogliosis suppression and lack of glial 
scar exacerbate pathology consequences increasing the subsequent neurologic deficit 
(Sofroniew, 2005). Proximal astrocytes respond through hypertrophy and biochemical 
remodelling (Verkhratsky et al., 2016)  
Thus, after neuronal damage, not only astrocytes isolate the injured area through 
formation of glial scars but they are also able to modulate inflammatory response, 
providing homeostatic protection to nervous tissues and the regulation of the synaptic 
network remodelling.  
In addition, astrocytes release molecules which can reduce BBB permeability enhancing its 
recovery.  
For all these reasons, astrocytes are essential for post-traumatic regeneration of nervous 




1.6. CNS infections 
 
CNS infection can be caused by bacteria, virus, fungi, and parasites and classified in 
meningitis, encephalitis or cerebral abscess. Reactive astrocytes and microglia are often 
indispensable for damage limitation. Astrocytes responses to pathology depend mostly on 
the nature of pathogen agent. Infections caused by Gram+ bacteria, as Pneumococcus and 
Staphylococcus, rapidly trigger astrogliosis insurgence leading to astrocytes hypertrophy 
and GFAP expression up-regulation (Iovine et al., 2013), secretion of pro-inflammatory 
factors as TNF-α (Li et al., 2012) and interleukin, and toll-like receptor TLR2 activation (Esen 
et al., 2004).  
It was also reported that bacterial infections can down-regulate the expression of gap 
junctions-forming connexin (Esen et al., 2007).  
Gram- bacteria can trigger an early astrogliosis, which increases with astrocytes 
proliferation (Chauhan et al., 2008; Dotevall et al., 1996). On the other hand, the astrocytes 
response to viral infection results more complicated, primarily because astrocytes can be 
a target for infection, as in HIV dementia. Astrogliosis and degeneration associated with 
astrocyte death have been associated with those pathological conditions. Loss of astrocytic 
functionality, thus, might contribute to the cognitive decline through a general decrease of 
astrocytes homeostatic support to neurons (Churchill et al., 2009).  
 
1.7. Toxic Injury 
 
- Encephalopathy from heavy metal  
  
Astrocytes represent the major target of encephalopathy due to exposition to toxic heavy 
metal concentration. Accumulation of those metals in astrocytic through membrane 
transporter may lead to EAAT1/2 glutamate transporter downregulation, compromising 
physiologic glutamate uptake (Struys-Ponsar et al., 2000; Verkhratsky et al., 2013; Yin et 
al., 2007).  
Such condition elicits excitotoxicity with subsequent neuronal death and 
neurotransmission disruption.   
 




The increase of ammonium concentration in CNS can provoke several mental and 
behavioural symptoms as confusion, irritability or consciousness alteration (Brusilow et al., 
2010; Butterworth, 2011; Felipo, 2013)   
For many decades, it was believed that hyperammonemia affected the astrocytes-specific 
glutamine synthetase which metabolizes ammonia synthesizing glutamine (Albrecht et al., 
2010; Rose et al., 2013)  
However, the pathological potential of astrocytes resulted to be more complex: recent 
studies pointed out that under high ammonia concentration conditions astrocytes go 
towards a rapid functional remodelling compromising their homeostatic functions.  
In details, are included:  
- K+ buffer failure (Obara-Michlewska et al., 2014; Rangroo Thrane et al., 2013)   
- aberration in Ca2+ signal and homeostasis (Haack et al., 2014; Wang et al., 2015)  
- abnormal calcium signalling leading to glutamate exocytosis (Gorg et al., 2010; Montana 
et al., 2014)  
- pathological increase of Na+ cytoplasmic concentration and H+ transport impairment 
causing alteration of pH regulation (Kelly et al., 2009; Kelly and Rose, 2010).   
 
1.8. Ischemic stroke 
 
Astrocytes role in stroke pathophysiology is multifaceted (Gleichman and Carmichael, 
2014). After stroke insurgence and ischemic core formation, astrocytes from the peripheric 
zone (the penumbra) become key elements in the limitation of the ischemic lesion and the 
neurological deficit (Verkhratsky et al., 2016).  
Astrocytes are the major neuroprotective element in the penumbra zone, through the 
control of ions and glutamate concentrations and providing nutrient supply to neurons. In 
fact, an exasperated neuronal death rate can be observed after inducing a stress condition 
in astrocytes (Sayre et al., 2014). Since astrocytes play a key role in glutamate excitotoxicity 
control: GLT1 transporter downregulation, indeed, increases the area of the injured lesion 
(Rao et al., 2001) while its overexpression reduces the area dimension and limit 
neurological deficits (Harvey et al., 2011). Maintenance of glutathione, ascorbic acid and 
ROS buffer system plays an important neuroprotective role in post-stroke tissues (Dringen 




1.9. Epilepsy  
 
Epilepsy is a CNS pathology characterized by seizures, affecting around the 2% of world 
population (Hesdorffer et al., 2011). To date, anti-epileptic drug-discovery focused on 
molecules targeting neuronal cells.  
However, several studies demonstrated that astrocytes under epilepsy conditions are 
subjected to pathological remodelling and might represent a new pharmacological target. 
Those cells show a phenotype characterized by changes in ion channels, receptors and 
transporters, which lead to a general disruption of astrocytes-dependent homeostasis in 
the damaged areas (Bedner et al., 2015; Steinhauser et al., 2015).  
Under epilepsy conditions, astrocytes display a phenotype characterized by modification 
of ionic channles, receptors, and transporters which compromise the astrocyte-dependent 
homeostasis in the damaged areas.  
Studies on patient tissues or murine models revealed the abnormal electrophysiological 
properties of astrocytes and the complete lack of intercellular coupling between astrocytes 
mediated by gap junctions (Bedner et al., 2015). Furthermore, alterations of Cx43/Cx30 
connexin and increase of GFAP expression have been observed (Steinhauser et al., 2012). 
Astrocytes role in epilepsy pathophysiology appear related to the dysregulation of K+-
mediated buffering system, in which potassium channels Kir4.1 are involved. In fact, both 
ion flow density mediated by these channels and the expression of Kir4.1 itself are reduced 
in a sclerotic area of human hippocampus (Heuser et al., 2010; Hinterkeuser et al., 2010; 
Steinhauser et al., 2015).   
Others pathological changes compromise glutamate uptake (Coulter and Eid, 2012) or 
decrease GS expression in neurons, with a subsequent decrease of GABA synthesis, 
favouring the occurrence of epileptic crisis (Benedetti et al., 2011; Wang et al., 2009). 
Astrocytes can affect neuronal excitability caused by changes of adenosine kinase (ADK) 
expression with effects on adenosine homeostasis (Aronica et al., 2013; Boison and 
Aronica, 2015). Li and colleagues showed that an increase of ADK expression in astrocytes 
reduces adenosine availability, which in turn enhances higher neuronal excitability, 





1.10. Neuropsychiatric pathology: Schizophrenia 
 
According to the current view, abnormalities in neuronal network and a general 
dysregulation of neurotransmission might be the major pathological mechanisms of 
schizophrenia (Laruelle, 2014; Muller and Schwarz, 2006; Rubinov and Bullmore, 2013). 
Since astrocytes are fundamental for synaptogenesis and sustainment of glutamatergic 
transmission, their possible involvement in schizophrenia onset has been increasingly 
investigated (Bernstein et al., 2015; Sanacora and Banasr, 2013; Verkhratsky et al., 2014; 
Xia et al., 2014).  
A lower number and density of astroglial cells was detected in diverse cerebral region of 
patients affected by schizophrenia (Rajkowska et al., 2002; Schmitt et al., 2009; Webster et 
al., 2001). Xia and colleagues detected a significative decrease of the expression of 
astrocytes-specific proteins, fundamental for CNS homeostasis, such as AQP4 or 
membrane glutamate transporter. Thus, authors advanced the hypothesis that astrocytes 
subpopulation localized in cortex might be harmed during schizophrenia progression (Xia 
et al., 2014).    
In addition, the expression of the cistin/glutamate exchanger Sxc-, able to regulate 
glutamate release and control its extracellular concentration, resulted to be decreased in 
an animal model for schizophrenia.  
Furthermore, the metabolism of the endogenous NMDA receptor positive modulator D-
serine presents alterations.   
Post-mortem analysis showed lower production of kynurenic acid in brain tissues of 
psychiatric patients. Kynurenic acid is a tryptophan metabolite mainly produced by 
astrocytes and acting as endogenous inhibitor of acetylcholine and NMDA receptors.  
All these data suggest that astrocytes under schizophrenic conditions present functional 
deficits in controlling glutamatergic transmission and might therefore a key factor in this 
pathology (Laruelle, 2014).  
 
1.11. Neurodegenerative pathologies 
 
-Alzheimer’s Disease  
 
Alzheimer Disease (AD) is a chronic neurodegenerative pathology whose etiology remains 
unknown (Verkhratsky et al., 2010). AD is characterized by senile plaques composed of 
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extracellular B-amiloid accumulation and neurofibrillary tangles constituted of 
phosphorylated tau protein (Selkoe, 2001).  
Morphological and functional modifications occur in astrocytes during AD early stages, 
mainly characterized by atrophy, while astrocytes number remains constant (Beauquis et 
al., 2014; Kulijewicz-Nawrot et al., 2012; Olabarria et al., 2010; Verkhratsky et al., 2010; 
Yeh et al., 2011).   
Atrophic astrocytes are not able to accomplish their homeostatic functions, leading to 
irreversible modifications in brain, disruption of the synaptic network, and early cognitive 
deficit. Since astrocytes play a key role in synaptogenesis and synapses maintenance 
(Verkhratsky and Nedergaard, 2014), their alteration can cause to a decrease or loss of 
synaptic activity, representing the early stage in pathology progression (Verkhratsky et al., 
2014a, 2010).  
Furthermore, astrocytes atrophy compromise β-amiloid clearance (Kimura et al., 2014). 
In addition, a progressive reduction of glucose metabolism has been observed during AD 
early stages, due to modifications of neurons and astrocytes (Mosconi et al., 2008).  
Since astrocytes present a significative glicolitic pathway, it is likely that alteration of 
glucose metabolism results deeply harmful for these cells (Verkhratsky et al., 2016).  
The scientist Alois Alzheimer observed for the first time the presence of hypertrophic glial 
cells surrounding both damaged neurons and senile plaques. Recent post-mortem analysis 
carried out on brain of patients affected by AD revealed the upregulation of main 
astrocytes markers such as GFAP and S100B. Many studies demonstrated that high 
concentration of β-amiloid can modulate the expression of protein involved in Ca2+ 
signalling pathways and homeostasis in cultured astrocytes (Grolla et al., 2013; Lim et al., 
2014), eliciting the downregulation of the expression of glutamate transporters (Matos et 
al., 2008). However, little is known about molecular pathways underlying such 
mechanisms. Despite therapies against AD resulted to be limited and ineffective, recent 
results described a prominent role of astrocytes in neurodegenerative pathologies, 
proposing these cells as a possible pharmacological target in future therapies (Verkhratsky 






1.12. Amyotrophic Lateral Sclerosis (ALS) 
 
ALS is a chronic neurodegenerative and untreatable pathology, with unknown etiology. It 
is characterized by the loss of muscular functions due to a progressive neuromuscular 
weakening and spasticity (Verkhratsky et al., 2016). Astrocytes seem to be involved in 
mechanisms responsible to SLA-related neuronal damaging. In theory, these cells might 
contribute to neuronal death both directly (releasing neurotoxic substances) and indirectly 
(through the loss of homeostatic and protective functions) (Verkhratsky et al., 2016). 
Slower progression of the pathology and longer life expectancy can be observed in 
transgenic animals subjected to the transplant of wild-type astroglial precursors (Lepore et 
al., 2008). Papadeas and colleagues demonstrated that transplantation of astrocytes 
carrying a mutated copy of the gene hSOD1 in spinal cord of wild-type rodents triggers 
motoneurons degeneration and peculiar SLA symptomatology (Papadeas et al., 2011).  
In vitro experiments confirmed the pathological role of astroglia in ALS: neurons and 
motoneurons co-culture demonstrated that astrocytes are responsible for the synthesis of 
molecules harmful for neurons (Bilsland et al., 2008; Di Giorgio et al., 2008; Ferraiuolo et 
al., 2011; Haidet-Phillips et al., 2011; Marchetto et al., 2008; Nagai et al., 2007; Phatnani et 
al., 2013). Such factors include: excess of extracellular glutamate and D-serine, increase of 
prostaglandin E2 secretion, massive interferon-y release, TNF-β secretion, nerve growth 
factor (NGF) and lipocalin 2 release (Valori et al., 2014). 
 
1.13. Parkinson’s Diseases (PD) 
 
To date, astrocytes involvement in Parkinson’s disease pathogenesis has been scarcely 
studied.  
Several toxins play a key role in PD onset and astrocytes might represent a target for that 
substances (Rappold and Tieu, 2010). For instance, MPTP, a lipophilic substance 
accumulated in astrocytes, can be converted in the toxic metabolite MPP+ by MAO-β. MPP+ 
is then released from astrocytes and up-taken by dopaminergic neurons, where 
compromises ATP synthesis and increases ROS production causing neuronal death 
(Meredith et al., 2008).  
MAO-β is mostly expressed in astrocytes (Ekblom et al., 1993) and its levels increase 
proportionally with age, a risk factor for PD. In addition, the expression of such enzymes is 
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correlated to neuronal death in substantia nigra (Mahy et al., 2000; Mandel et al., 2003). 
Global level of glutathione, mostly produced by astrocytes, are significantly lower (40%) in 
Parkinson’s disease and this could indicate a lack in astrocytic protection against oxidative 
stress (Rappold and Tieu, 2010).   
Astrocytes contain proteins related to the pathologies such as α-sinuclein (AS), parkin and 
phospho-tau: it was demonstrated that such cells are able to accumulate AS and produce 
massive Lewy’s bodies in vitro (Lee et al., 2010).  
Interestingly, only protoplasmic astrocytes display high amount of AS in cytoplasm, while 
no evident changes of AS levels have never been detected in fibrous astrocytes (Song et 
al., 2009). Since AS accumulation increases astrocytes sensitivity to oxidative stress leading 
to apoptosis, protoplasmic astrocytes degeneration could occur in all synucleinopathies 
(Song et al., 2009).  
Finally, many researches pointed out the role of the astrocytic protein S100B, which can 
act both as a cytokine or a protein associated to the inflammation or neurodegenerative-












The aim of this thesis is the investigation of the release pathways  in astrocytes and 
their role in signal transmission in the  central nervous system.  
The research was addressed towards three research lines:  
- release of exosomes from astrocytic processes 
- modulation of release of the gliotransmitter glutamate from astrocytic processes 
by putative receptor-receptor interactions between D2, A2A and Oxytocine (OXT) 
receptors 
- effect of low energy laser light on the release of glutamate from astrocyte processes 
as compared to the release from nerve terminals  
Investigation on these topics might shed a new light, respectively; on  
- the pattern for astrocyte-neuron communication network and the ability of 
astrocytes to send messages through non-classical signalling; 
- the role of astrocytes in signal integration in CNS, through allosteric interactions 
between membrane GPCRs and their control on the release of the 
gliotransmitter glutamate 



















The methods here reported concern the techniques applied in the works described in 
detail in this thesis.  




Adult male rats (Sprague-Dawley 200-250 g) and mice (C56Bl6J) were housed at the animal 
house of Pharmacy Department (DIFAR) of the University of Genova. Water and food were 
freely available. Temperature (22± 1°C), relative humidity (50%), and light/dark schedule 
were continuously monitored.   
Experimental protocols and animal care observed the European Communities Parliament 
and Council Directive of 22 September 2010 (2010/63/EU) and with the Italian D.L. n. 26/ 
2014, and were approved by the Italian Ministry of Health (protocol number 26768 of 
November 2012 and protocol number 75F11.N.6JI of August 2018), in accordance with 
Decreto Ministeriale 116/1992. All possible efforts were made to minimize the quantity of 
animals used and their suffering.   
 
2. Isolation of purified astrocytic processes and nerve terminals 
 
Brain tissues (rat striatum, mouse cerebral cortex) were removed after rat decapitation 
and quickly placed in ice-cold medium. Purified gliosomes (resealed astrocytic processes) 
were prepared according to Nakamura’s protocol (Nakamura et al., 1993), as previously 
reported (Stigliani et al., 2006; Cervetto et al., 2015, 2016)  
Tissues were homogenized in 10 volumes of 10mM Tris/HCl pH 7.4 with 0.32 M sucrose, 
using a glass-Teflon tissue grinder (clearance 0.25 mm). After centrifugation (5 min, 1000g 
4°C) to remove debris and nuclei, the homogenate was stratified on a discontinuous Percoll 
gradient (2, 6, 10, 20 % v/v in Tris buffered sucrose) and then centrifuged (5 min, 33500g; 
4°C). Gliosomes are purified astrocytic processes containing vesicles loaded with 
gliotransmitters and are harvested in the interlayer between 2% and 6% (v/v) Percoll layers. 
During release experiments purified gliosomes were resuspended in a HEPES buffered 
medium additioned with NaCl 128, KCl 2.4, MgSO4 1.2, KH2PO4 1.2, CaCl2 1.0, and HEPES 
10 con glucose 10, pH 7.4 (concentration expressed in mM). Protein determinations were 
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carried out according to Bradford (1976).  
 
3. Release of endogenous glutamate and [3H]D-Aspartate   
 
Superfusion technique (Raiteri M et al., 1974; Raiteri L. et al., 2000) was applied to 
investigate the release of endogenouse glutamate or [3H]D-Aspartate from astrocytic 
processes (Cervetto et al., 2015; Cervetto et al, 2016; Cervetto et al., 2017; Marcoli et al, 
2017) and synaptosomes.  
One of the major advantages of that techniques was that superfused gliosomes were 
subjected to a condition defined as “naked” receptor: continuous perfusion, indeed, 
constantly removes released substances avoiding the instauration of a receptor biophase. 
Thus, that experimental model could be used for the pharmacological characterization of 
receptors which can modulate the release of transmitters or the analysis of receptor-
receptor interactions   
Since previous stuides did not observe differences in the behaviour of tritium or 
endogenous release from astrocytic processes obtained from rodent brain, [3H]D-
Aspartate can be used to investigate glutamate release form perfused gliosomes. 
Gliosomes were incubated with 0.03 µM for 15 minutes at 37°C and then superfused. 
For experiment with homocystein, 4mM homocystein was added during tissue 
homogenizaztion. Gliosomes entrapped homocystein and were then perfused.  
Briefly, equal samples of gliosomes (or synaptosomes) were distributed at the bottom of 
up to 20 parallel chambers of the perfusion apparatus; after 33 minutes of perfusion 
necessary to stabilize the release processes, the perfusion liquid can be harvested. Liquid 
collection was divided in fractions lasting 3 minutes each (from b1 fraction, starting at t=33’ 
and ending at t=36’, to b6 or b7 according to the experimental protocol).   
At t=38’, gliosomes were stimulated for 6 minutes with either depolarizing stimulus or 
agonist. The antagonists were added 8 min before the agonists, when necessary.  
During each experiment, at least one chamber was perfused with standard medium as a 
control. 
Resuspended gliosomes or synaptosomes were distributed on parallel chamber and the 
effects of the single substance on endogenous glutamate release was quantified in 
triplicate. The endogenous glutamate released in the collected fractions was measured by 
HPLC analysis (Waters Alliance, Milford, MA, USA): the analysis involves an automatic pre-
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column derivatization with o-phthalaldehyde, the separation on a C18 reverse phase 
chromatography column (Chrompack International, Middleburg, The Netherlands), 
fluorimetric detection and the amino-acid homoserine was used as the internal standard. 
The limit of detection was 100 fmol/μL (Marcoli, M et al, 2004).  
The amounts of glutamate in the collected samples were expressed as pmol/mg protein. 
The effect of the compounds (or depolarization) on the glutamate efflux was calculated as 
overflow by subtracting the basal release in the control chambers from the total amount 
of glutamate released during stimulation in substance-treated chambers (or in chambers 
supplemented with 4-AP).  
In a subset of laser experiments, synaptosomes were incubated with rose bengal (0.5 µM) 
30 minutes at 3 °C in the dark, and then perfused.  
 
4. Immunohistochemistry and confocal microscopy  
 
Gliosomes and synaptosomes (15-20 ug) have been fixed with 2% paraformaldehyde for 
15’, permeabilized with 0.2 % Triton X-100 for 5’ and incubated for 60’ with primary 
antibody diluted in 3% albumin PBS (p/v). The used primary antibodies were the following: 
mouse anti-synaptophysin (1:1000; Sigma-Aldrich, St. Louis, 61 MO, USA), mouse or rabbit 
anti-fibrillary acidic protein (GFAP; 1:1000; Sigma-Aldrich); mouse anti-oligodendrocyte 
(RIP; 1:10000; Merck Millipore Corporation, Darmstadt, Germany), mouse anti-integrin αM 
(clone OX-42; 1:25; Merck Millipore Corporation), guinea pig anti-VGLUT1 (1:1000; 
Synaptic Systems, Goettingen, Germany), mouse anti-VGLUT1 (1:500; Synaptic Systems), 
rabbit anti-A2A (1:200; Alomone Labs, Jerusalem, Israel; AAR-002), mouse anti-D2 (1:200; 
Merck Millipore Corporation; AB5084P), rabbit anti-D2 (1:200; Atlas Antibodies, 
Stockholm, Sweden), rabbit anti-D2 (1:200; Alomone Labs; ADR-002) mouse anti-OXTR 
(1:200; Santa Cruz; sc-515809). Once incubated with primary antibodies (overnight, 4°C), 
samples were washed with PBS and then incubated for 60 minutes with the matched 
conjugated secondary antibodies diluted in 3% albumin PBS. A three channel TCS SP2 laser-
scanning confocal microscopy was used to acquire images.   
The purity of gliosomes and synaptosomes prepared from cerebral cortex was evaluated 
using specific astrocytic and neuronal markers, anti-GFAP, anti-synaptophysin, and 
antibodies usually used for labelling oligodendrocytes and microglia, anti-RIP or anti-




5. Preparation and perfusion of slices  
 
Cerebral cortex were chopped to obtain 250 μm slices, which were then transferred to 
parallel superfusion chambers (37°C) and the constantly superfused with standard medium 
(mM: 125 NaCl, 3 KCl, 12 MgSO4, 1,2 CaCl, 1 NaH2PO4, 22 NaHCO3, 10 glucose, gassed with 
95% O2, 5% CO2, pH 7,4). Liquid was collected in 5-minutes samples. After 30 minutes, slices 
were subjected to the laser light stimulation (60 J/cm2, 1 W, 60s).  
 
6. Laser parameters and experimental design  
 
Slices, synaptosomes or gliosomes were transferred on the superfusion chambers, which 
we wrapped with aluminium foil to avoid light dispersion, and then exposed to laser 
stimulation, more precisely a near-infrared diode laser by the AB2799 hand-piece (Doctor 
Smile, LAMBDA Spa, Vicenza, Italy). Chosen parameters were the following: 808-nm 
wavelength, 1 or 0.1 W of power, 1 or 0.1 W/cm2 irradiance in CW (pulse energy of 0 Hz).
Ca2+-free medium was used to study calcium role in laser-evoked glutamate 
release.  
 
7. Vescicle isolation from perfused astrocyte processes  
 
Vescicle released from perfused astrocyte procssese were analyzed. Perfusion experiments 
were carried out as previously described (See Marcoli et al., 2008; Cervetto et al., 2010). 
Briefly, astrocyte processes purified from adult male rat cortex were transferred on parallel 
chambers and perfused with physiological medium at a constant flow (0.5 ml/min). After 5 
minutes, perfused liquid was harvested in one 10 minutes long collection. The sample was 
the ultracentrifuged (110.000g for 70 minutes) to isolate the exosomes (Guescini et al., 
2010). The pellet was then resuspended as follows: 
- in PBS for DLS (Dynamic light scattering) analysis with the Zeta sizer nano ZS90 (Malvern 
Instruments) to determine vesicle dimension  
- in lysis buffer (Laemli buffer) to carry out Western Blot analysis . 
The ultracentrifuged sample was diluted with 0.22 μm filtered PBS to obtain the optimal 
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parameters suitable with the DLS analysis. The analysis had a 60 seconds duration and was 
carried out at 25°C. Sample light reflection was scattered 90° in comparison with the 
incidence line of the laser.  
 
8. Electron Microscopy 
 
Gliosomes and exosomes were studied through ultrastructural analysis performed by 
negative staining method. In brief, 5μl drops of gliosomes or purified exosomes were put 
onto formvar and carbon-coated copper grids and adsorbed for 20 min at RT. A filter paper 
was used to remove the excess of buffer. Then, grids were fixed in 2% PFAin PBS (pH=7.2) 
for 5 min and rinsed three times with distilled water. Grids were then incubated for 5 min 
at RT with 1% uranyl acetate aqueous solution. Contrast enhancement was obtained 
incubating the grids with a mixture of 1% uranyl acetate and 1% methylcellulose for 5 min. 
After drying, grids with gliosomes or exosomes were immediately observed with a CM10 
electron microscope (Philips, Eindhoven, The Netherlands). Digital images were taken with 
a Megaview II camera. 
 
9. Exosomes labeling 
 
The exosome pellet was resuspended in diluent C and then labelled using the PKH67 dye 
according to the producer's technical bulletin (Fitzner et al.,2011). After gently pipetting 
the dye with the sample, and waiting for 5 min at room temperature, the staining reaction 
was stopped bringing the volume up to 35ml with 10% BSA in PBS. Exosome pellet was then 
obtained by ultracentrifugation (110.000 g for 90 min) and then resuspended in 150 μl of 
Neurobasal. As control condition, we prepared a samples with equal volumes of PBS plus 
the same amount of diluent C, PKH67 dye, 10% BSA and PBS, and by omitting the exosomes, 
in order to exclude non-specific labeling of cells due to micelles of the aliphatic dye or to 
the excess of dye itself.  
 
10. Neuron-Astrocyte Co-Cultures  
 
Primary cortical cells were edrived from Sprague–Dawley rat embryonic day 18 (E18). 
Culture preparation was performed as follow. Briefly, an E18 timed pregnant Sprague–
Dawley female rat was euthanized by CO2 and cervically dislocated in accordance with 
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institutionally approved animal care. Embryos were dissected and cortices isolated in 
Hank's buffer solution without Ca2+ and Mg2+. All tissues were collected and maintained in 
ice-cold buffer solution and, cerebral cortices were enzymatically digested at 37°C with 
warm TrypLe Express for 15–18 min in a water bath to obtain a single-cell suspension. The 
digestion was stopped by adding medium (Neurobasal or DMEM) complemented with 10% 
FCS (fetal calf serum) for 3 min. After that, medium was carefully removed and the cortices, 
transferred in Neurobasal/B27 (supplemented with Glutamax and Pen- Strepto), were 
mechanically triturated with a sterile firepolished Pasteur pipette. Single-cell suspension 
was well mixed, counted, and finally diluted. Cells were plated on poly-L-ornithine (100 
μg/ml) coated-coverslips placed into multiwells plates at the density around 5.0x 
104cell/cm2. The primary cultures were kept at 37°C in humidified atmosphere of 5% CO2 
in air. The culture medium was changed weekly, until the uptake experiments at 21 DIV. 
After 3 weeks of development, the percentage composition of the cell population was 
distributed with 70 ± 15% of neurons and 30 ± 15% of glial cell (the percentage of neurons 
and astrocytes were estimated in three to five nonoverlapping fields from three different 
cultures, and are expressed as mean ± SEM). Immunofluorescence assays were performed 
using rabbit anti-MAP-2 (1:500), mouse anti-GFAP (1:1,000), and DAPI dye. 
 
11.   Cellular Uptake of Exosomes  
 
Exosomes were lebelled with the fluorescent PKH67 lipophilic dye and dispersed (16 μl) in 
the cell culture medium and incubated for 1 h at 37°C in humidified atmosphere of 5% 
CO2 in air., the same volume (16 μl) of control sample was added in the medium of other 
coverslips from the same neuronal preparation, as a negative control and incubated for 1 
h under the same 
conditions as above. After one hour, both the coverslips with the exosomes and the control 
sample were repeatedly rinse to remove the excess.Uptake capabilities of the exosomes 
was evaluated by experiments repeated on three different neuronal preparations, 
developed in vitro for 3 weeks, and the biological sample was subjected to specific staining 
to confirm both its neuronal/glial morphology and exosomes uptake. Briefly, cells were 
fixed in 4% PFA, blocked with 3% BSA, and incubated with rabbit or mouse primary 
antibodies (over-night at 4°C in humid chamber) and then with Alexa Fluor 546 donkey 
anti-mouse and 633 goat anti-rabbit (1h at room temperature). The following primary 
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antibodies were used: rabbit anti-β III tubulin (1:500) or rabbit anti-MAP2 (1:500), or rabbit 
or mouse anti-GFAP (1:1,000). The antibodies in excess were washed out by PBS. The glass 
coverslips were mounted with antifade mounting medium and observed at the confocal 
microscopy.  
 
12.   Materials 
 
4-aminopyridine (4-AP), homocysteine (Hcy), 7-(2-phenylethyl)-5-amino-2-(2-furyl)-
pyrazolo-[4,3-e]-1,2,4 triazolo[1,5-c]pyrimidine (SCH 58261), sulpiride, quinpirole and rose 
bengal were from Sigma-Aldrich. Oxytocin and L- -371,257 were bought from Tocis. When 
possible, drugs were dissolved in distilled water or in physiological medium. SCH 58261 and 
sulpiride were dissolved in DMSO, then diluted 1:1000 in HEPES medium. 
PKH67 dye and homocystein were purchased from Sigma-Aldrich. 
 
13.   Statistical analysis  
 
The data related to the study of endogenous release were reported as the mean values ± 
SEM (standard error of the mean) of n experiments, indicated in the legends of the 
individual figures. The significance of the differences was evaluated using the one-way 
ANOVA and then the Bonferroni post hoc test and with a statistical significance placed at 













1. LASER STIMULATION ON CORTICAL ASTROCYTIC PROCESSES AND 
NERVE TERMINALS 
 
Almost all the living organisms can spontaneously emit photons known as biophotons. 
Although many effects of photon have been reported also in the central nervous system, 
their ability to determine the release of neurotransmitters or gliotransmitters in CNS has 
been scarcely investigated. Here, we evaluated whether photons stimulation can 
determine the  release  of the gliotransmitter/neurotransmitter glutamate from different 
models, and investigated the source of the released glutamate and the mechanisms 
involved.  
 
1.1. Cortical gliosomes and synaptosomes are purified preparations 
 
Immunohistochemistry analysis carried out before the beginning of my PhD showed that 
synaptosomes and gliosomes are purified preparations expressing, respectively, neuronal 
and astrocytic markers.  
As shown in the figure below, indeed, synaptosomes showed positivity to anti-
synaptophysin antibody, while no reactivity was observed for anti-GFAP, RIP or Integrin αM 
antibodies, indicating the absence of contamination from astrocytes, oligodendrocytes or 
microglia.  
On the other hand, gliosomes were positive to GFAP labelling, with neglectable neuronal, 






Fig. 2 Synaptosomes and gliosomes are highly purified preparations  
Cortical synaptosomes and gliosomes were labelled with anti-synaptophysin, GFAP, RIP and Integrin αM 
antibodies to detect possible contamination. Synaptosomes and gliosomes resulted positive exclusively for 
neuronal (synaptophysin) and astrocytic (GFAP) markers, respectively. Scale bares are indicated in the 
images. 
 
1.2. Laser light evokes glutamate release from mice cortex slices 
  
Previous experiments on laser light application were carried out in prof. Marcoli’s lab, using 
cortical slices and nerve terminals.  
Perfused cortex slices were stimulated with laser light (See Material and Methods). The 
amount of endogenous glutamate released during perfusion was significantly higher in 
comparison with control.  
Slices are a suitable model to mimic neuron-astrocytes network communication since they 









Fig.3 Photons evoke glutamate release from mouse cerebral cortex slices.  
Representative time course of endogenous glutamate release from cerebral cortex slices perfused with 
physiological medium (1.2mM Ca2+;  basal condition; ∆ laser stimulation). Laser stimulation (60 J/cm2, 
1 W, 60 secondi) was applied during perfusion. Furhter details in Material and Methods section. 
Insert. The column represents the increase of endogenous gluatamte releas evoked by laser light. The 
result is indicated as the mean ± SEM di n= 3 indipendent experiments.  
 
1.3. Effects of laser light on gliosomes  
 
Since photons stimulation evoked glutamate release from cortical slices, the next step was 
to figure out which cell population was responsible for this phenomenon.  
To this aim, two different model were used: astrocytic processes and nerve terminals. 
As shown in Figure 4, laser light administration did not provoke any effect on glutamate 
release. It was possible to rule out, therefore, that the increase in glutamate release 







Fig. 4 Effects of photons on glutamate release from astrocytic processes.  
Representative time-course of endogenous glutamate released from gliosomes perfused with 
physiologic medium (1.2 mM Ca2+;  basal; ∆ laser stimulation). Laser (60 J/cm2, 1 W, 60 
seconds) stimulation was applied during the perfusion. Further details in Material and Methods 
section.  
Insert,The bar represents the amount of endougenos glutamate released from gliosomes 
perfused with standard medium after stimulation with laser light. The result is shown as the 
average ± SEM of n= 3 indipendent experiments. 
 
1.4. Laser light increases glutamate release in nerve terminals  
 
Once excluded that astrocytic processes might be involved in glutamatergic transmission 
evoked by laser, it was hypothesized that photons stimulation might induce glutamate 
release from nerve terminals. Synaptosomes stimulation by laser light, indeed, induced 
synaptosomes to release glutamate, as shown in Figure 5.  
Since the fact that the neurotransmitter release was due to the neuronal population, and 
not to the glial compartment, had been established by previous experiments, we decided 
to further investigate and characterize the phenomenon in the nerve terminals, to reveal 
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the mechanisms possibly involved in the absence of responsiveness of the astrocyte 
processes to photons, and in responsiveness of the nerve terminals. Thus, we wondered 
whether the release was dependent on extracellular Ca2+ concentration and mediated by 
vesicles.  
Laser administration to nerve terminals perfused with Ca2+-free medium (Figure 5, insert) 
or treated with the V-GLUT-1 inhibitor Rose Bengal determined a significant reduction of 
glutamate release in comparison with the control (Figure 6, insert), confirming that the 




Fig. 5 Laser effects on nerve terminals  
Representative time-course of endogenous glutamate released from synaptosomes perfused with 
physiologic medium (1.2 mM Ca2+;  basal; ▲ laser stimulation). Laser stimulation was applied during 
the perfusion. Further details in Material and Methods section.  
Insert. Bars represent the laser-evoked endogenous glutamate from perfused synaptosomes in normal 
conditions (black) or Ca2+-free medium (white). The result is shown as the mean ± SEM of n= 3 
indipendent experiments.  
*** p< 0.001 vs 1W laser in standard medium (1.2 mM Ca2+) one-way ANOVA followed by Bonferroni 








Fig. 6 Laser evokes a vesicular glutamate release from synaptosomes  
Representative time-course of endogenous glutamate released from nerve terminals. Control 
synaptosomes were stimulated with 1W laser (▲), or previously incubated with Rose Bengal (RB) and 
then perfused (●) or stimulated with laser (▲). 
Insert. Bars represent the laser-evoked endogenous glutamate from synaptosomes (black) or Rose 
Bengal-(dark-pink) treated synaptosomes. The result is shown as the mean ± SEM of n= 3 indipendent 
experiments. 
** p = 0.003 vs 1W laser in standard medium one-way ANOVA followed by Bonferroni post hoc test 
 
1.5. Glutamate release from cortical nerve terminals depends on laser power 
 
Results obtained with 1 W laser suggested that stimulation with photons provoke a large 
amount of glutamate release from nerve terminals, suggesting that the selected power 
might not be suitable to study physiologic processes as glutamate release in response to 
photons in our model. Thus, we wondered whether a 0.1 W laser was able to stimulate 
lower amount of glutamate release from nerve terminals.  
The results confirmed our hypothesis, demonstrating that the release from cortical nervous 
terminal is dose-dependent (Figure.7). Interestingly, nerve terminals treated with Rose 
Bengal and then stimulated with 0.1 W laser released significantly lower quantity of 
glutamate, suggesting that, also under those conditions, the release is vesicle-dependent 




Fig. 7. Glutamate release from cortical nerve terminals depends on laser power 
Representative time-course of endogenous glutamate released from nerve terminals. Synaptosomes did 
not received any stimulation (○) or were stimulated with 0.1 W (▼) or 1W laser (▲). 
Insert. Bars represent the laser-evoked endogenous glutamate from synaptosomes treated with only 0.1 
W laser (black) or Rose Bengal-treated synaptosomes stimulated with 0.1 W laser (dark-pink). The results 
are shown as the mean ± SEM of n= 3 indipendent experiments. 
** p = 0.003 vs 1W laser in standard medium one-way ANOVA followed by Bonferroni post hoc test 
 
1.6. Glutamate cannot be released from cortical astrocyte process also at lower 
laser power  
 
Also at 0.1 W, able to evoke a lower more “physiological” glutamate overflow from the 
nerve terminals, laser light was unable to stimulate any glutamate release from the 






2. MODULATION OF GLUTAMATE RELEASE BY RECEPTOR-RECEPTOR 
INTERACTIONS IN RAT STRIATAL ASTROCYTIC PROCESSES 
 
 
A2A-D2 Receptor-Receptor Interaction 
 
A research project directed towards the investigation of the expression of A2A-D2 
heterodimers in striatal astrocytes and their effects on the mechanisms controlling the 
release of glutamate in astrocytic processes led to the demonstration of functional, 
biochemical and biophysical interaction between the A2A and D2 receptor on stritatal 
astrocytes.The results were published in the following articles:  
 
Homocysteine and A2A-D2 receptor-receptor interaction at striatal astrocyte 
processes  
C. Cervetto, A. Venturini, D. Guidolin, G. Maura, M. Passalacqua, C. Tacchetti, P. Cortelli, 
S. Genedani, S. Candiani, P. Ramoino, S. Pelassa, M. Marcoli, L.F. Agnati 
J Mol Neurosci (2018)  
 
A2A-D2 Heteromers on Striatal Astrocytes: Biochemical and Biophysical 
Evidence. 
S. Pelassa, D. Guidolin, A. Venturini, M. Averna, G. Frumento, L. Campanini, R. Bernardi, 
P. Cortelli, GC. Buonaura, G. Maura, L.F. Agnati, C. Cervetto, M. Marcoli. 
Int J Mol Sci. 2019 May 17;20(10):2457. doi: 10.3390/ijms20102457 
(Supplement 1) 
 
The results published in the two papers abovementioned are here shortly reported: 
- Immunofluorescent analysis demonstrated that both D2 and A2A receptors are 
expressed on striatal astrocytic processes (see also Cervetto et al, 2017), and colocalize 
with the V-GLUT1 transporter (see Cevetto et al, 2018 and Supplement 1). 
Functional interactions were studied using the superfusion method (See Material and 
Methods). Gliosomes were stimulated with the depolarizing agent 4-AP alone or with D2 
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and A2A agonists or antagonists (see Cervetto et al, 2018). Results showed that the D2 
agonist quinpirole decreases 4-AP-evoked glutamate release from gliosomes in 
comparison with the control (4-AP alone). The effect was actually mediated by the D2 
receptor, as the D2 antagonist sulpiride abolished the quinpirole-evoked inhibitory effect 
on glutamate release.  
Although the administration of the A2A agonist CGS21680 didn’t show any effect on the 
level of released glutamate, the stimulation with both quinpirole and CGS21680 caused 
the release of amount of glutamate comparable with the control (see Figure 8). Taken 
together, these data suggest that A2A and D2 receptor are colocalized in astrocytic 
processes and control glutamate release through functional interactions. Furthermore, 
gliosomes were treated with D2 synthetic peptide VLRRRKRVN, corresponding to the D2 
receptor intracytoplasmatic region involved in electrostatic interactions with the A2A 
receptor occurring during receptor heteromerization. VLRRRKRVN-gliosomes treated with 
quinpirole and CGS21680 as previously reported, showed that the synthetic peptide 
abolished the effect of A2A receptor on D2-mediated inhibition of 4-AP-evoked glutamate 
release, indicating that A2A and D2 receptors have physical interaction at the level of the 
intracytoplasmatic tail (see also Cervetto et al, 2017). Intracellular (but not extracellular) 
homocysteine was able to reduce the D2- mediated inhibition of glutamate release. Even 
in presence of intracellular homocysteine, astrocytic A2A receptors were still capable of 
interacting with D2 receptors (see Figure 8). The effect of intracellular homocysteine, able 
to reduce the D2-mediated inhibition of glutamate release (allosteric action of 
homocysteine on D2), and not interfering with the ability of the A2A receptor to abolish 
the D2 effect (therefore maintaining A2A-D2 interaction) indicate the complexity of A2A-






Fig.8 Intracellular Homocystein effect in astrocytic processes  
The A2A agonist CGS2168 is able to abolish the quinpirole-mediated inhibition of 4-AP-evoked glutamate 
release (white bars, black bars). Intracellular homocysteine interferes with the quinpirole-mediated 
inhibitory effect on the 4-AP-evoked glutamate release (black bars) in comparison with the control (white 
bats). Bars represent percentage increase of [3H]-D-Aspartate in the presence of the drugs of the 
concentration indicated.  
*p < 0.05 compared with the effect of 4-AP alone. #p < 0.05 compared with the effect of 4-AP plus quinpirole 
in the absence of homocysteine.  
From Cervetto et al, 2018. 
 
 
Physical interactions between the two receptors were demonstrated by Proximity 
Legation Assay (PLA) and co-immunoprecipitation (Supplement 1).   
Co-immunoprecipitation results, in particular, demonstrated that all D2 receptors 
expressed in striatal astrocytic processes have a physical interaction with the A2A 
receptors, while not all the A2A receptor were connected to D2 receptors.  
Taken together, all this data demonstrated that A2A and D2 receptors expressed on 
striatal astrocytic processes form heterodimers with functional and physical interactions. 
Heterodimers between Oxytocin and D2 receptors have been previously reported in rats 
striatum (Romero-Fernandez et al., 2013).  
After demonstrating A2A-D2 heterodimer existence, we focused on the study of the 
possible OXT-D2-A2A receptors interactions in astrocytic processes. 
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2.1. EXPRESSION OF OXT RECEPTORS IN FRESHLY ISOLATED 
ASTROCYTES FROM RAT STRIATUM 
 
2.1.1. OXT receptor is expressed on astrocyte processes of adult rat striatum 
 
Gliosomes purified from adult rat striatum were labelled with anti-OXTR and anti-GFAP 
antibodies. Immunofluorescence analysis indicated that oxytocin receptors were 




 Fig.9 Rat striatal purified astrocyte processes express OXT receptors.   
Confocal microscopy analysis. Immunofluorescence for GFAP (green) and for the OXT receptor (red): merge 
image showing co-expression of the markers. Scale bare is indicated in the image. 
 
Moreover, further immunofluorescence analysis were performed using an anti-VGLUT1 
primary antibody to investigate the expression of oxytocin receptors in V-GLUT-1 positive 
gliosomes. 
We obtained the evidence that oxytocin receptors are localized on glutamatergic 








Fig.10 Rat striatal purified astrocyte processes endowed with the V-GLUT1 transporter 
express OXT receptors.  
Confocal microscopy analysis. Immunofluorescence for GFAP (green), OXT receptor (red), and VGLUT1 
(blue): merge image showing co-expression of the markers (white dots). Scale bare is indicated in the 
image. 
 
2.1.2. OXT receptors control glutamate release from striatal astrocytic processes  
 
Since oxytocin receptors are expressed in gliosomes endowed with V-GLUT1, we wondered 
whether OXT receptors were able to control the mechanisms underlying glutamate release 
in astrocytic processes.  
Gliosomes were then stimulated with the depolarizing agent 4-AP in addition with:  
- oxytocin  
- oxytocin in presence of the oxytocin antagonist L-371,257   
Oxytocin (0.003 μM) inhibited the glutamate release response evoked by the 4-AP; while 
the OXT antagonist L-371,257 (0.1 μM), per se ineffective on the 4-AP-evoked endogenous 
glutamate release, prevented the oxytocin inhibition of the release (Figure 11). This data 
indicates the presence of oxytocin receptors negatively coupled to the release of glutamate 





Fig. 11 Oxytocin receptor controls the glutamate release from striatal astrocytic processes 
Striatal astrocytic processes in perfusion were stimulated with the depolarazing agent 4-AP (300 µM), 
Oxytocin (0.003 µM) and oxytocin receptor antagonist L-371,257 (0.1 µM), as indicated in the figure. 
The results are shown as the mean ± SEM of n= 3 indipendent experiments.  
*** p<0.01 one way ANOVA followed by Bonferroni post hoc test vs 4AP.  
 
2.1.3. OXT and A2A receptors are co-expressed in striatal astrocytic processes  
 
In striatal astrocyte processes, the presence of heteromers A2A-D2 was previously 
demonstrated with physical and biochemical evidence (Pelassa et al., 2019) and fuctional 
evidence. (Cervetto et al., 2017, 2018). As D2, the OXT receptors were involved in 
modulating the release of glutamate from striatal processes; by immunofluorescence and 
release experiments we tested if OXTR had physically or functionally interactions with the 
A2A receptor, as previously reported by our group for the D2 receptor.  
Immunofluorescent analysis showed that OXT and A2A receptors were co-expressed in the 









Fig.12 Rat striatal purified astrocyte processes express OXT and A2A receptors  
Confocal microscopy analysis. Immunofluorescence for GFAP (green), OXT receptor (red), and A2A receptor 
(blue): merge image showing co-expression of the markers (white dots). Scale bare is indicated in the image. 
 
2.1.4. OXT and A2A receptors functionally interact in striatal astrocyte processes  
 
As immunofluorescent results demonstrated the existence of both A2A and OXT receptors 
on the same astrocytic processes, we hypothesized that these receptors may functionally 
interact. By studying the effects of oxytocin agonist and antagonist, and of A2A receptor 
agonist and antagonist, we found that oxytocin was able to inhibit the depolarization-
evoked release of endogenous glutamate from the astrocyte processes, following a pattern 
sensitive to the OXT receptor antagonist L-371,257, indicating the presence of release-
inhibitory receptors for oxytocin. Activation of the A2A receptor, per se ineffective on the 
release of glutamate, was able to revert the inhibitory action of oxytocin, in a way sensitive 





Fig. 13 Functional interaction between Oxytocin and A2A receptors   
Striatal astrocytic processes in perfusion were stimulated with the depolarazing agent 4-AP (300 µM), in 
the presence of the used drugs: oxytocin (0.003 µM), A2A receptor agonist CGS21680 (0.01 µM), A2A 
receptor antagonist SCH58261 (1 µM) or the OXT antagonist L-371,257 (0.1 µM). The antagonists SCH 
58261 and L-371,257 were added 8 minutes before the agonists (see Materials and Methods).The results 
are shown as the mean ± SEM of n=10 for 4-AP; + oxytocin; + oxytocin & CGS 21680;   
n=5 for 4AP + CGS21680; + oxytocin &CGS 21680 & SCH 58261; +oxytocin &CGS 21680 & SCH 58261 & L-
371,257; n=3 for 4-AP + SCH 58261. 
*** p<0.01 one-way ANOVA followed by Bonferroni post hoc test vs 4AP  
 
Taken together, the results indicate a functional interaction between A2A and OXT 






2.1.5. OXT and D2 receptors are co-expressed in striatal astrocytic processes   
 
As previously observed, the OXT activation inhibited the 4-AP-evoked glutamate release as 
the dopamine D2 receptor (Cervetto et al., 2017). Moreover, we recently demonstrated 
the presence of A2A-D2 heteromers in striatal astrocytes with a functional role in the 
modulation of glutamate transmission. Here we carried out immunofluorescence analysis 
to figure out whether OXT, A2A and D2 receptor were colocalized on the same astrocytic 
process (Figure 12).  
Results showed that the three receptors are expressed on the same gliosome, suggesting 





Fig. 14 Rat striatal astrocyte processes express OXT, A2A, and D2 receptors.  
Confocal microscopy analysis on striatal gliosomes. Immunofluorescence for OXTR (red), A2A (green), and D2 
receptor (blue): merge image showing co-expression of the receptors (white dots). Scale bare is indicated in 
the image.  
 
2.1.6. Do OXT and D2 receptor have functional interaction in striatal astrocytes 
processes? 
 
To verify the hypothesis that OXT, A2A and D2 receptors might form heterocomplex in 
striatal astrocytic processes, we evaluated the possible functional interactions between 
OXTR and D2 receptors stimulating gliosomes in perfusion with 4-AP in presence of the 
oxytocin and D2 receptor agonists (oxytocin and quinpirole) and antagonists (L-371,257 
and sulpiride). In striatal astrocytic processes, the D2 receptor agonist quinpirole (1 μM) 
inhibited the glutamate releasing response to 4-AP; the D2 receptor antagonist sulpiride 
(10 μM), per se ineffective on the 4-AP-evoked glutamate release, prevented the 
quinpirole-evoked inhibition of the release (Figure 15).  
The co-presence of the two agonists, oxytocin and quinpirole, produced a more intense 
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inhibition than each agonist alone (Figure 15), confirming the reported evidence of the 
dopamine D2-oxytocin receptor heteromers in striatum with facilitatory receptor-receptor 
interactions (Romero-Fernadez et al., 2013). Coadministration of sulpiride plus L-371,257 
was able to completely prevent inhibition of the glutamate release due to the co-presence 






Fig. 15 Oxytocin and D2 receptors control the glutamate release in striatal astrocytic 
processes   
Striatal astrocytic processes in perfusion were stimulated with the depolarazing agent 4-AP (300 µM) in 
the presence of the used drugs: oxytocin (0.003 µM), D2 receptor agonist quinpirole (1 µM), D2 receptor 
antagonist sulpiride (10 µM) or the OXT antagonist L-371,257 (0.1 µM). The antagonists sulpiride and L-
371,257 were added 8 minutes before the agonists (see Materials and Methods). The results are shown 
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as the mean ± SEM of n= 8 for 4AP; 4AP + oxytocin; n= 4 for 4AP + quinpirole; n= 7 for 4AP + quinpirole 
& sulpiride; for 4AP + quinirole & oxytocin; n=3 all the others. 
 *** p<0.01 one-way ANOVA followed by Bonferroni post hoc test vs 4AP.  
# <0.01 one-way ANOVA followed by Bonferroni post hoc test vs 4AP & oxytocin or 4AP & quinpirole 
 
As expected, experiments confirmed that individual stimulation of oxytocin or D2 receptor 
determines a lower amount of glutamate release from gliosomes.  
However, simultaneous stimulation of both the receptors leads to a higher inhibition of 
glutamate release from astrocytic processes. Results from perfusion experiments show 
that, apparently, D2 and oxytocin receptors could present functional interactions.  
Additional experiments are necessary, using a no-effective quinpirole concentration, since 
is reported that oxytocin is able to increase the Bmax value for D2 receptor antagonist at 
D2 receptor, without a change in the KD value of the D2-likeR antagonist [3H]–raclopride-
binding sites in striatal membrane preparations (Romero-Fernadez et al., 2013).  
In any case, our results indicate that glutamate release from astrocyte processes can be 
modulated also by activation of oxytocin receptors, and by a receptor-receptor interaction 
between A2A and oxytocin receptors.  
Further experiments will be requested to completely understand whether functional 
interactions occur not only between OXT and D2 receptors but also among OXT, A2A, and 
D2 receptors, and if the functional interaction might depend on receptor heteromerization 







3. EXOSOMES RELEASE FROM ASTROCYTIC PROCESSES 
 
The release of nanovesicles (exosomes) from astrocytic processes is one of the research 
lines in prof. Marcoli’s lab. Results were published in the following manuscript:  
  
 
Exosomes From Astrocyte Processes: Signaling to Neurons  
Venturini A, Passalacqua M, Pelassa S, Pastorino F, Tedesco M, Cortese K, Gagliani 
MC, Leo G, Maura G, Guidolin D, Agnati LF, Marcoli M, Cervetto C.  
Front Pharmacol. 2019 Dec 2;10:1452. doi: 10.3389/fphar.2019.01452.  
(Supplement 3) 
 
Here, we provided a brief summary of the results obtained: 
 
- Electron microscopy analysis showed that astrocyte processes purified from adult rat 
cortex are endowed with the Multivesicular bodies and could release extracellular vesicles 
when perfused with buffered physiologic medium. Collected nanovesicles were then 





Fig. 16 Electron microscopy image of a single cortical astrocyte process. 
In a gliosome, vesicles scattered in the cytoplasm and a multivesicular body are shown. Scale bar: 200 




DLS analysis on purified vesicles showed that their size distribution (range 50-75 nm, 
peaking at 60nm) was compatible with the exosomes reported size (10-100 nm, 
Doyle,2019). Imaging analysis showed that vesicles released from astrocytic processes 
have the typical bell-shape and size as exosomes.  
Finally, blot experiments demonstrated that gliosomes-derived vesicles express the typical 
exosomes markers TGS 101 and Alix19. In addition, they resulted positive even for 
astrocytic marker GFAP and ezrin. Taken together, these results strongly suggested that 
vesicles released form rat cortical astrocytic processes are exosomes.  
Even though exosomes release from astrocytes had been already demonstrated in culture 
cells, this is, to our knowledge, the first demonstration that astrocytic processes derived 




Fig. 17 Characterization of rat cerebrocortical astrocyte processes-released exosomes. 
Electron microscopy images of a vesicle released from astrocyte processes. The cup shape 
appearance and its size, consistent with previously reported exosome electron microscopy 
images characteristics. Scale bar: 100 nm. For experimental details, see Materials and Methods. 
 
 
Interestingly, exosomes were positive for the protein Neuroglobin (NGB), a protein with 
anti-oxidant, apoptotic, and inflammatory effects. 
- Exosomes from astrocytic processes seem to be able to target neurons in a neuron-
astrocytes mixed co-culture. Primary cortical cells from rat embryonic day 18 were cultured 
and differentiated in neurons and astrocytes. The neuron-astrocytes co-cultures were then 




Confocal imagines showed that exosomes are up-taken selectively from cultured neuronal 
cells. 
In conclusion, our work demonstrated that astrocytic processes purified from rat cortex 
can release exosomes which, in turn, can be up-taken from in vitro neuronal cells. It can be 
hypothesized that exosomes have a protective role in CNS, carrying the NGB protein which 







Fig. 18  Neurons as targets for the exosomes.   
The confocal analysis showed exosomes targeting neurons when added to a neuron-astrocyte co-culture.  
Exosomes marked with PKH67 (green) selectively target MAP2 (red, B, C) or β III tubulin (red, D) – positive 
neurons, while GFAP-positive astrocytes are not targeted (red in E). The showed images are the merge 
of a single z stack of the two channels (A-D) or representative maximum intensity projections of the 
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acquired z stacks of the two channels (E). Scale bars are indicated in the images. For other experimental 
















We here investigated the possible link between photobiomoduation (PBM), a manipulation 
of cells occurring through the emission of light from a light source, and glutamate-releasing 
cells in CNS.  
In fact, it is recognized that almost all the living organisms can spontaneously emit photons 
both under physiological or pathological conditions, known as biophotons (Devaraj et al., 
1997; Prasad and Pospíšil, 2013). The emission is strictly related to the physiological and 
pathological conditions of the organisms (Moraes et al., 2012; Bertogna et al., 2013). 
Bioluminescence phenomenon is well known since a long time, for instance light-emitting 
fireflies.  
Biophotons existence was postulated in 1920 by Gurwitsch (Gurvitch et al., 1926) but, due 
to the lack of technology, they were never detected. In 1955, Colli (Colli et al., 1955), 
observed for the first time the biophotons presence in plant thanks to the use of 
photomultiplier tubes, at that time just invented. During the 60s and 70s, scientists were 
interested in mechanisms underlying biophotons generation, proposing the hypothesis 
according to whom that processes might be related to mitochondrial respiration, lipidic 
oxidation, and other metabolic processes (Vladimirov et al., 1971; Zhuravlev et al., 1973). 
Numerous experiments demonstrated that free radicals, reactive species and their 
derivates can play an important role in the regulation of cellular processes and, since their 
production is the result of well determined processes, it is likely that even biophoton 
production follows a well-regulated pathway and play a role in cell signalling (Dröge, 2002; 
Lee et al., 2013).  
Thanks to Popp’s studies, DNA is recognized as a source of biophoton. Popp himself 
proposed the theory of biophotonic coherent radiation, hypothesizing the existence of an 
electromagnetic field in the cell which might be behind cell communication (Popp et al., 
1984; Popp and Belousov, 2003).   
Photobiomoduation (PBM) was discovered fifty years ago and its role in human and 
veterinary medicine has been increasingly recognized (Amaroli et al., 2018). The story of 
PBM starts thanks to Endre Mester in 1967, the pioneer of photobiomodulation, who first 
observed electromagnetic field in cells. However, Prof. Karu was the first to propose a 
model explaining the mechanisms through which laser might interact with target cells 
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(Karu, 1986). Nowadays, PBM is defined as a manipulation of cells occurring through the 
emission of light from a light source. Once in cells, photons are able to interact with specific 
molecules called photoacceptors and induce a photochemical reaction in the cell itself 
(Hamblin and Demodova, 2006). As a matter of fact, effects of photons in mammals have 
been known for 50 years, and their effects were associated with increase of intracellular 
Ca2+ and NO synthesis in cells (Amaroli, 2017).  
PBM is a therapy based on the administration of non-thermic light from the near infrared 
(NIR) (600-1000 nm) emitted by a laser or a non-coherent light source. PBM is able to 
produce beneficial effects in patients affected by many pathologies. The high numbers of 
reports which, recently, showed PBM positive effects for treatment of lesions and 
pathology of the nervous system, is a sign of the increasing interest for 
photobiomodulation and its applications (Huang et al., 2014). Interestingly, PBM 
application was proposed to be effective for many clinical procedures in murine models 
(Wu Q, 2012; Henderson 2015). Therapy application on animal model, therefore, 
demonstrated that PBM is able to enhance memory recovery (Karu et al, 1989), axon 
growth and nerve regeneration (Byrnes et al., 2005; Rochkind, 2009), and neuron 
protection from neurotoxic damage (Oron et al., 2006; De Taboada et al., 2006). PBM 
efficacy on nervous system was further demonstrated by studies carried out on mice 
affected by stroke event or post-traumatic lesions (TBI): those animals, once therapies was 
administrated, showed a better neurological and functional recovery (Oron et al., 2006; 
Lapchak and Taboada, 2010; Oron et al., 2007; Quirk et al., 2012). Moreover, twelve-
months CD1 mice treated with PBM presented better emotional (decrease stress) and 
mnemonic responses (Michalikova et al., 2008).  
After applying PBM on humans, encouraging results were obtained in terms of tissue 
regeneration, wound healing (Albertini et al., 2007), and neuron protection from 
neurotoxic lesions (Wong-Riley et al., 2005; Liang et al., 2008). Furthermore, PBM applied 
on subjects who suffered for a trauma resulted to reduce the inflammation (Aimbire et al., 
2006), enhance anti-inflammatory effects (Brosseau et al., 2000), reduce the edema 
(Stergioulas et al, 2004), and restore the issues of blood streaming (Avci et al., 2013), 
finding the application in diverse field of medicine aimed to the treatment of 
muscleskeletical lesions, skin diseases, degenerative pathology, and syndrome caused by 
neuropathic pain (Hopkins et al., 2004; Xuan et al., 2013). In addition, many other data 
support PBM application in diverse biomedical areas, including endodontia (a branch of the 
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odontoiatry), oral pathologies treatment, oral surgery, and orthodontia (Milward et al., 
2014). PBM application can prevent pain and protect muscles before intensive workout, 
implying a wide use of of that technology as a preanesthetic assessment before surgical 
procedures (Agrawal et al., 2014).  
On the other hand, some studies suggested that PBM is uneffective or even potentially 
harmful (Tunér and Hode, 1998; Bjordal et al., 2003). Non significative effects may be 
explained with non-proper dosimetry, wrong energy level, irradiance, and time of 
exposition (Tunér and Hode, 1998; Hunag et al., 2009; Ilice t al., 2006).   
It is known that the cells that make up the nervous system are able to communicate via 
chemical or electrical signals. In addition, it has been shown that such cells are able to emit 
biophotons: this emission can be modulated by depolarizing stimuli (as shown by Artem'ev 
et al., 1967) or by the presence of glutamate (as shown by Tang and collaborators on mouse 
bark slices; Tang and Dai, 2014).  
To date, only hypotheses exist regarding the production pathways of such biophotons in 
nervous system. For example, some scholars believe that they could originate from 
mitochondria and then propagate through nerve fiber microtubules (Tang and Dai, 2014). 
Many studies in literature described the effects of photons on the physiology of the central 
nervous system. In fact, several experiments carried out on cultured neurons showed that 
laser light is able to modify the membrane potential of mitochondria, ATP levels, 
intracellular Ca2+ levels, and the production of reactive species of oxygen and nitric oxide 
(NO) (Huang et al., 2014; Amaroli et al., 2015 and 2016). It was demonstrated that laser 
light can modify the redox state of the cell producing ROS or increasing cellular reductive 
capacity (Oron et al., 2012).  
However, the mechanisms through which laser light acts on the functioning of the nervous 
system have not yet been fully understood. One hypothesis is that laser light might act on 
neurotransmission processes by modifying the abovementioned mechanisms. In fact, some 
studies have shown a correlation between changes in mitochondrial membrane potential 
and ATP synthesis levels and have been linked to the ability of the neuron to release 
neurotransmitters (Choi et al., 2009; Rangaraju et al., 2014).  
Regarding the relationship between photons and neurotransmitter release, we need to 
focus on two molecules known for their role in cellular signal modulation and involved in 
the mechanisms that lead to the release of neurotransmitters: calcium and nitric oxide 
(NO). The former is a second messenger fundamental for the exocytotic release of vesicles 
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(Barclay et al., 2005) while, according to some studies, NO could play a role in the regulation 
of neurotransmitter release (Prast and Philippu, 2001; Garthwaite, 2008).   
Therefore, for a better understanding of the mechanisms through which laser light acts on 
the functioning of the nervous system, we investigated on photons effects on the release 
of glutamate by taking advantage of different preparations from the rodent cerebral 
cortex, slices - maintaining neuron-astrocyte relationships - and purified astrocyte 
processes and nerve terminals.   
 
1.1 Cerebral cortex slices release glutamate if stimulated with low-intensity 
laser light 
 
 The major advantage of cerebral cortex slices is that they maintain intact the interactions 
between cells, efficiently mimicking the in vivo conditions.  
During our experiments, perfused slices from rat cerebral cortex were stimulated with laser 
light (See Material and Methods), determining an increase of the amount of glutamate in 
comparison with the control, and confirming the ability of PBM to enhance glutamatergic 
transmission in CNS. 
As slices maintain neuron-astrocyte networks, and since both neurons and astrocytes can 
release glutamate, results from those experiment do not allow to understand which cell 
population respond to the laser stimulation.  
 
1.2. Laser light did not evoke glutamate release from astrocytic processes but 
evoked it from nerve terminals 
 
Since cortical slices represent both neuronal and glia cells responses to stimulus, we were 
interested to understand which cell population was the source of the released glutamate. 
Experiments showed that stimulated astrocytic processes did not release glutamate, while 
nervous terminals did.  
This result is consistent with the data reported by Golovynska and colleagues, who 
demonstrated that the application of laser light at different wavelength (including the 808 
nm) determines Ca2+ influx and membrane depolarization in neuronal cells (Golovynska, 
2020). 
On the other hand, astrocytic processes did not show any response to the stimulus. 
According to our knowledge, administration of low laser therapy was never directly 
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experimented on astrocytes, except for a study published by Sun and colleague, who 
applied PBM on murine model of Spinal Cord Injury. According to their study, PBM 
significantly reduces the activation of astrocytes and the secretion of chondroitin sulfate 
proteoglycans from the cells (Sun 2020).   
 We can rule out that glutamate release was due to membrane damage caused by the light 
because the amount of glutamate levels increases during stimulus administration and then 
decreases to basal levels after stimulus cessation, as shown in the time-course.  
However, we must keep in consideration that PBM targets mitochondrial cytochrome in 
cells (Poyton,2011). According to ultrastructural analysis, astrocytic processes, differently 
from nerve terminals, are not endowed with mitochondria. So, we cannot exclude that 
inability of photons to evoke glutamate release from the astrocyte processes is dependent 
on the absence of mitochondria in gliosomes.  
The exposition of nerve terminals to laser stimulation causes an impressive release of 
glutamate, much higher than the amount we usually observe using different stimuli (data 
not shown). Although photons emission was proposed to be involved in CNS signal 
transmission (Tang,2014; Kumar2016), the amount of glutamate released after laser 
stimulation was too high for physiologic processes. Thus, we realized that, probably, laser 
parameters were not suitable for our perfusion model. Accordingly, we modified laser 
parameters in order to obtain lower power laser.  
 
1.3. Glutamate release at 0.1 W laser 
 
Since protocols for photobiomodulation application are variable and no agreement on the 
parameters (as laser power, intensity or wavelength) (Zein et al,2018) that should be used 
has been reached, we wondered whether the release of glutamate from nerve terminals 
was laser power-dependent. The quantity of glutamate evoked from synaptosomes treated 
with the 0.1W laser, indeed, was significantly lower than the glutamate released from 
synaptosomes stimulated with 1 W. Experiments with Rose Bengal demonstrated that also 
in this case, the glutamate release from the nerve terminals was vesicle-dependent. Taken 
together, considering that excitotoxicity of glutamate at high concentration, this result 
might indicate that the choice of parameters for phtobiomodulation application should be 
accurate in order to avoid release of glutamate possibly harmful for the individuals. 
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On the other hand, also at 0.1W, laser could not evoke any release of glutamate from the 
astrocyte processs. Further investigation is required to understand the reason for the 
ineffectiveness of PBM on astrocytic release. Indeed, by exploring the mechanisms possibly 
involved in the glutamate releasing effect from the nerve terminals, and specifically by 
investigating on the possible involvement of different Ca2+ channels types, of NO signalling, 
or of mechanisms related to mitochondria function, it will be possible to get light on the 
effectiveness and ineffectiveness of PBM on transmitter release from different cell types 
in the CNS. As a matter of help, these investigations would also help to obtain a greater 








2 MODULATION OF GLUTAMATE RELEASE BY RECEPTOR-RECEPTOR 
INTERACTIONS IN RAT STRIATAL ASTROCYTIC PROCESSES  
 
 
2.1 G-protein coupled receptors can form heteromers in CNS  
 
G-protein coupled receptors (GPCRs) are important proteins expressed on cell membrane 
which play a fundamental role in detecting signals from the extracellular space (Rozenfeld 
et al, 2010).  
As known, GPCRs are a key receptor family involved in numerous physiological processes 
and for this reason they represent the target of many drugs (40-50% of drugs currently on 
the market).  
GPCRs activation causes signal transduction mediated by four Gα-protein subclasses (Gαs, 
Gαi, Gαq, and Gαo), leading to the regulation of many cellular events. Receptor stimulation 
causes changes in the levels of intracellular second messengers (mainly cAMP and Ca2+) 
and, often, involves Ser/Thr protein kinases and phosphatases (Brugarolas et al., 2014). 
During the ‘80s, it was observed that GPCRs do not exist only as individual receptors but 
can also assembly in oligomers, probably formed through the instauration of allosteric 
interaction between receptors (Agnati et al., 1980; Fuxe et al., 1983).  
Receptor heteromerization was described for many receptors, as for instance, mGLU, 
dopamine, adenosinergic, cannabinoids, and ocytocin receptors (Gomes et al., 2016, 
Cervetto et al., 2017, Perez de la Mora et al., 2016).  
The major aspect of heteromerization is that the proteins forming the heteromers acquire 
new properties which are different from the ones of the receptor alone: pharmacological 
responses and G-protein coupling are two examples (Rozenfeld et al., 2010).   
Noteworthy, heterodimers can be involved in pathological conditions (e.g: prostaglandin 
EP1 receptor-β2-AR heteromer in airway smooth muscles; this heteromerization reduces 
coupling of β2-AR to Gas, reducing the bronchodilatory potential of the β2-AR agonist 
isoproterenol), representing thus an important target for pharmacological therapies 
(McGraw et al., 2006).  
In CNS, GPCR heterodimers play a crucial role in the striatum, integrating signals from the 
dopaminergic and adenosinergic system. For instance, the response of striatal neurons to 
dopamine can be dependent on the expression of heteromers between adenosine and 
dopamine receptos. Furthermore, the occurrence of heteromers in models of Parkinson’s 
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disease was previously identified (Brugarolas et al.,2014)  
 
3.   Heterodimers on striatal astrocytes  
 
Data previously obtained in Prof. Marcoli’s lab provided the evidence of the existence of 
interactions between the A2A and D2 receptors expressed on astrocytes.  
The activation of A2A receptors reduced the D2-mediated inhibition of the 4-AP-evoked 
3[H]-D-aspartate release in gliosomes (Cervetto et al., 2017, 2018; Pelassa et al., 2019). 
Functional evidences suggested that the receptor–receptor interaction was based on 
heteromerization of native A2A and D2 receptors at the membrane of striatal astrocyte 
processes. Moreover, biochemical and biophysical evidences confirmed that the receptor–
receptor interaction between A2A and D2 receptors in 
astrocyte is based on A2A-D2 heteromerization (Pelassa et al., 2019). The co-
immunoprecipitation and proximity ligation assay approaches provided the evidence for 
the ability of native striatal astrocytic A2A and D2 receptors to heteromerize (Pelassa et al., 
2019).   
Therefore, the interactions between native A2A and D2 receptors on the striatal astrocyte 
processes might be due to the formation of receptor heterodimers. Here, the experimental 
evidences supporting the theory: 
 - A2A and D2 receptors result expressed on same striatal astrocytic processes (Cervetto 
et al., 2017, 2018);  
 - A2A and D2 receptors functionally interact in the control of the release of the 
gliotransmitter glutamate Cervetto et al., 2017, 2018);  
 - A2A and D2 receptors can form heterodimers on astrocytes through physical 
interactions (Pelassa et al., 2019).  
Notably, the heteromers were able to modulate the release of the gliotransmitter 
glutamate from the processes, indicating that native striatal astrocytic A2A-D2 receptors 
via allosteric receptor–receptor interactions could play a role in the control of striatal 
glutamatergic transmission. Also, the findings indicate the involvement of striatal 
astrocytes in A2A and D2 receptor signal transmission.   
Data here presented suggest that also oxytocin (OXT) receptors are likely involved in 
oligomeric structures in striatal astrocytes processes purified from adult rats.  
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2.3 .  Oxytocin is a G-protein coupled receptor 
 
Oxytocin is a nonapeptide produced and released in the brain where it works as a 
neurotransmitter (Perez de La Mora et al.,2016). Oxytocin is involved in many functions, 
including not only sexual and maternal behavioural but also anxiety, sociability and even 
drug abuse (Jurek et al,2018). Oxytocin binds and activates its receptor, a G-protein 
coupled receptor which activate Gq, Gi or Go proteins when stimulated.  
BRET experiments on transfected HEK293 cells demonstrated that OXTR stimulated with 
Oxytocin interacts with Gq, Gi, and Go proteins (Busnelli et al., 2010).  
 
2.4 .  Oxytocin receptor can form heterodimers 
 
As many GPCRs, even oxytocin receptors might be able to interact with other GPCRs and 
form oligomeric structures. Perez de la Mora and colleagues, indeed, demonstrated that 
the dopamine receptor D2 interacts with the oxytocin receptor in HEK293 cells and suggest 
the existence of D2-OXT heterodimers in rats amydgala playing a role in fear/anxiety 
control (Perez de la Mora et al., 2016).  
Proofs of the existence of D2-OXTR heterodimers in murine striatal neurons were provided 
by Romero-Fernandez and colleagues through Proximity Ligation Assay experiments. 
Interestingly, the authors found that oxytocin significantly increased the affinity of the high 
(KiH) affinity agonist state of the D2R in association with an increase in the D2Rs density in 
the ventral striatum (Romero-Fernandez et al, 2013).  
  
2.5 .  Oxytocin receptors are expressed in striatal astrocytic processes and control 
glutamate release 
 
Immunochemistry analysis showed that the oxytocin receptors are expressed in astrocytic 
processes purified from adult rats. Since OXTR colocalized with the glutamate transporter 
V-GLUT1, we used the perfusion technique to investigate whether oxytocin receptor 
activation may affect the glutamate release from astrocytic processes.  
Gliosomes were stimulated with the depolarizing agent 4-AP in presence of the agonist 
oxytocin leading to an inhibition in the endogenous glutamate efflux. Thus, this data 
showed that the oxytocin receptor can actually interact with the pathways underlying 
gliotransmitter release in astrocytic processes, reducing the amount of glutamate released 
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from astrocytic processes following depolarization. As previously described for D2 receptor 
(Cervetto et, 2017), also oxytocin receptor can control and decrease 4-AP-evoked 
glutamate release.  
2.6. Oxytocin receptor colocalizes with A2A and D2 receptors on striatal astrocytic 
processes 
 
Further confocal imaging analysis demonstrated that OXT receptors colocalize with A2A 
and D2 receptors. In particular, striatal astrocytic processes co-express OXT, A2A and D2 
receptors. Since A2A and D2 are well known to form heterodimers involved in the control 
of glutamate release from striatal processes (Cervetto et al., 2017, 2018; Pelassa et al., 
2019), it was possible to hypothesize that OXTR might be involved in similar functions. 
Thus, data suggest that receptor-receptor interaction might occur between OXT, D2, and 
A2A receptor. We thus wondered if functional interactions between OXT and D2 or A2A 
receptors may occur. As already mentioned, physical interactions between OXT and D2 
receptors were reported in rat striatal neurons (Romero-Fernandez, 2013) and 
hypothesized in amygdala (Perez de la Mora, 2016).  
Here, we evaluated whether functional interactions were involved in the modulation of the 
glutamate efflux the astrocytes processes (Romero-Fernandez W et al., 2013).   
 
2.7. Do OXT-A2A receptors functionally interact in striatal astrocytic processes?  
 
As previously mentioned, A2A-D2 heterodimers are present in striatum astrocyte 
processes and can control the astrocyte glutamate release. The activation of A2A receptors 
reduced the D2-mediated inhibition of the 4-AP-evoked 3H]-D-aspartate release in 
gliosomes (Cervetto et al., 2017, 2018; Pelassa et al., 2019). Functional evidences suggested 
that the receptor–receptor interaction was based on heteromerization of native A2A and 
D2 receptors at the membrane of striatal astrocyte processes; co-immunoprecipitation and 
proximity ligation assay confirmed that the receptor–receptor interaction between A2A 
and D2 receptors at the astrocyte is based on A2A-D2 heteromerization (Pelassa et al., 
2019).   
Here, we described that the A2A receptor reduced the OXT-mediated inhibition of the 4AP-
evoked glutamate release, which indicates the presence of a functional receptor-receptor 
interaction between A2A and OXT receptors in rat striatal astrocytes processes. We must 
highlight that the A2A receptor activation was per se unable to affect the glutamate release 
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from striatal astrocyte processes (see also Cervetto et al., 2017, 2018). Nevertheless, A2A 
receptor abolished the inhibition of glutamate release depending on the activation of D2 
receptors, demonstrating the receptor-receptor interaction through which D2 and A2A 
receptors regulate release of striatal astrocytic glutamate (Cervetto et al., 2017, 2018). 
Similarly, here we report the ability of the A2A receptor to abolish the oxytocin-mediated 
inhibition of the 4-AP-evoked glutamate release from striatal glisomes. Although OXT and 
A2A receptors seem to have a functional interaction, further experiments are necessary to 
demonstrate whether they can also physically interact.  
 
2.8. Do OXTR and D2 receptors functionally interact in striatal astrocytic processes? 
 
Physical interactions between OXT and D2 receptors were reported in rat striatal neurons 
(Romero-Fernandez et al., 2013) and hypothesized in amygdala (Perez de la Mora et al., 
2016). 
Here, we evaluated whether a functional interaction between OXT and D2 receptors was 
involved in the modulation of the glutamate efflux from the astrocytes processes.  
In superfusion experiments studying the 4-AP-evoked glutamate release from striatal 
gliosomes, both D2 than OXT receptor activations inhibited the gliotransmitter efflux. The 
co-activation of the receptors induced a stronger and significant inhibition of the glutamate 
release than a single receptor agonist, quinpirole (1 µM) for D2 or oxytocin (3 nM) for OXTR. 
To our knowledge, at the used agonist concentrations, it doesn’t seem that D2 and OXTR 
could interact each other; in fact, the strong inhibition obtained with the contemporary D2 
and OXTR activation might be the sum of the single agonist effects. Further experiments 
are needed to evaluate whether, at a lower and ineffective quinpirole concentration, the 
OXT receptor activation could behave similarly to what observed in striatal neurons 
(Romero-Fernandez W et al., 2013). This receptor-receptor interaction could be more in 
deep investigated, even considering our previous observation: in particular, we found that 
the D2 receptor expressed in striatal gliosome membrane almost completely 
immunoprecipitated with the A2A receptor. On the contrary, only a fraction of the A2A 
receptor immunoprecipitated together with the D2 receptor.  
In conclusion, further experiments are warranted to understand whether the oxytocin 





3. EXOSOMES RELEASE FROM ASTROCYTIC PROCESSES 
 
The main results obtained in this study can be summarized as follows: 
- gliosomes perfused with standard physiological medium release MVs positive for the 
exosome markers ALIX and TSG 101; 
- the MVs released by astrocyte processes and purified through ultrafiltration have 
dimensions that are compatible with those of the exosomes; 
- the exosomes released from cerebrocortical gliosomes also carry the characteristic 
proteins of the cells of origin. 
The significance of the data obtained and reported here should be considered in the 
context of the current state of knowledge on the role of EVs and in particular of exosomes 
in communication in the central nervous system under physiological and pathological 
conditions, and in the possible spread of signals of damage or neuroprotection, as well as 
in their intended use for diagnostic or therapeutic purposes. In particular, the following 
considerations can be made: 
- Although it was already demonstrated that exosomes can be released from astrocytes in 
culture (Guescini et al., 2012), in vitro astrocytes mimic only marginally the behaviour of 
the cells in physiologic conditions. The experiments reported here were carried out on 
astrocyte processes prepared from adult rat cerebral cortex, thus reflecting the 
characteristics of astrocyte processes in a mature neuron-astrocyte cerebrocortical 
network. These processes resulted positive for ezrin, an astrocyte cytoskeletal protein and 
selective marker of perisynaptic astrocyte processes (Derouiche, 2003), necessary for the 
structural plasticity of astrocyte processes (Lavialle et al., 2011; Bernardinelli et al., 2014). 
Vesicles positive for exosomes markers, as the proteins of the endosomal-lysosomal 
complex Alix and Tsg101, were found in the perfusate, indicating that the exosomes can be 
released from astrocyte processes.  
Astrocyte processes might therefore participate in the roamer-type volume transmission 
through the release of exosomes.  
Astrocytes could therefore be able to contribute in many ways to the transmission of 
signals in the CNS, both by receiving and sending messages of different types, and 
presumably with different target, such as gliotransmitters (e.g. glutamate, which can be 
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rapidly recaptured and/or activate non-synaptic glutamate receptors) or molecules that 
can be carried within nanovesicles. These mechanisms could contribute to a shift towards 
a neuro-astrocentric view of CNS functioning. In fact, the perisynaptic astrocyte processes 
could play a key role both for the classical volume transmission, through the release of 
gliotransmitters, and the non-classical roamer type volume transmission, through the 
release of exosomes. Through the latter, astrocytes would be able to induce transient 
phenotypes in the cells receiving the exosomes. Noteworthy, it was demonstrated that G 
proteins coupled receptors deriving from astrocytes and transported in exosomes can be 
uptaken and expressed in the receiving cells (Guescini et al, 2014).  
- It was found that exosomes can carry neuroglobin. Initially, it was believed that NGB in 
the mammalian CNS was expressed only in neurons (Laufs et al., 2004); later NGB was also 
observed in astrocytes and reactive astrocytes (Chen et al., 2005; Della Valle et al., 2010). 
Interstingly, it was hypothesized that NGB may be produced and secreted from astrocytes, 
probably as a neuro-protective agent for neurons (Della Valle et al., 2010). In fact, the role 
of astrocytes is well known as a significant source of neuroprotective mediators for neurons 
under pathological conditions (Masmoudi-Kouki et al., 2007). The possibility that astrocyte 
processes can release NGB through exosomes would allow them to send messages to 
distant cells, transiently modify their vulnerability to trauma, and contribute to the 
protective effects against ischemic damage (Gleichman and Carmichael, 2014; Verkhratsky 
et al., 2016).  
To date, it is well known that NGB can play several crucial roles in cell defense and 
resistance to degeneration: in this context, the transport of NGB from astrocytes to 
neuronal cells could help to protect neurons.  
It cannot be excluded that NGB might transferred to other glial cells, such as neighboring 
astrocytes: that could be a mechanism aimed to increase the resistance of astrocytes to 
damage. 
It has been shown that oestradiol regulates NGB expression in both neurons and astrocytes 
through molecular mechanisms mediated by ERβ (De Marini et al., 2010; 2013), and this 
regulation could be part of the neuroprotective mechanisms implemented in astrocytes by 
oestradiol (De Marini set al., 2013; Estefania Acaz-Fonseca et al., 2014; Guidolin et al., 
2016). On the other hand, the production of NGB in astrocytes in response to damage (also 
considering the possibility of hormonal regulation) and the sending of messages through 
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NGB could work as a protective mechanism for the neighboring cells belonging to the 
neuron-astrocyte network. 
- Since exosomes are released from a large variety of cell types, they have been proposed 
as peripheral markers for diagnostic-prognostic purposes for several diseases, including 
those of the CNS. However, one of the problems affecting their reliability as markers, 
besides the correct classification of exosomes, is their origin: most of the exosomes 
recovered in plasma are generated by endothelial cells. Therefore, the discovery that 
exosomes derived from astrocytes are positive for GFAP and ezrin astrocyte markers allows 
to hypothesize that the analysis of these markers could give a contribution to the 
identification of the cellular origin of exosomes from peripheral blood, both under 
physiological and pathological conditions of the CNS.  
- Further experiments demonstrated that exosomes released from astrocytic processes 
purified from cortex of adult rats can be up-taken by cultured neurons.  
Although it is well known that cultured astrocytes can release exosomes able to target the 
co-cultured neurons, this is, to our knowledge, the first demonstration that ex-vivo 
astrocytes can release nanovesicles which, in turn, can be up-taken by neurons.  
Although we did not demonstrate that NGB levels in neurons increased upon exosomes 
administration, we can speculate that exosomes release from astrocytes can represent a 
new mode of astrocyte-neurons communication able to transfer molecular messages from 













In recent years, astrocytes role in CNS has been reconsidered assuming increasingly 
relevance in biomedical research. This cell population, indeed, is no longer considered 
merely as a glue or a protection for neurons, but also as key player in synaptic transmission 
and neuronal activity under both pathological and physiological conditions.  
Data presented in this thesis tried to investigated astrocytes functions and modes for 
signalling from astrocyte processes in different cerebral regions of murine brain (striatum 
and cortex) and in different contexts. 
 
1. Laser stimulation on cortical astrocytic processes and nerve terminals 
 
Stimulation with low intensity laser is a reality in odontoiatry and its therapeutic use 
against CNS pathology is currently under investigation. However, to our knowledge, no 
data about effects of laser light on neurotransmitter or gliotransmitter release in CNS were 
available.  
Photobiomodulation, also known as Low Laser Therapy (LLT), is the application of low 
intensity light for therapeutic purposes. Interest on photobiomodulation relies on the 
promise of a drug-free therapeutic approach employing light, which might be used not only 
to treat pain, promote reduction of inflammation and speed up wound healing, but also to 
promote tumours and cancer cell inhibition, and regeneration and restoration of various 
organism functions.  
Recently, the transcranial application of irradiation in 600–1070 nm wavelength range 
became increasingly considered as a new neuroprotective approach to treat 
neurodegenerative diseases (Golovynska, 2020).  
However, application of such therapy on human organisms requires a deep knowledge of 
the effects of light action.  
Our results indicate that photons can evoke glutamate release from mice cortex and, thus, 
may be involved in the astrocytes-neurons network interactions.  
Furthermore, laser application on astrocytic processes and nerve terminals provided the 
evidence that photon action is effective only on the latter. Notably, laser-evoked glutamate 
release was dependent on Ca2+ availability in the medium, strongly suggesting that the 
mechanism underlying the release is vesicular exocytotic mediated by vesicles. Vesicles 
involvement was confirmed by the use of the V-GLUT1-inhibitor Rose Bengal, which 
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dramatically decreased the glutamate release after photon stimulation.  
TTX effectiveness on synaptosomes stimulated with laser demonstrated that photons 
provoked membrane depolarization with Na+ channel involvement in nerve terminal. 
Mitochondria and ATP production are widely recognized targets for PBM, and presynaptic 
mitochondria and their capacity for ATP production are known to be related to the 
efficiency of synaptic vesicle exocytosis. Ultrastructural analysis showed that the nerve 
terminals are equipped with presynaptic mitochondria, while astrocytic processes are not. 
Although activation of mitochondrial ATP production might be related to the glutamate-
releasing effect of photons, further investigation is required for a better understanding of 
the ability of photons to activate vesicular glutamate release from the nerve terminals, and 
its inability to evoke glutamate release from the astrocyte processes. Indeed, we cannot 
exclude the participation of other mechanisms; for example, NO production - which is 
reported to be increased by laser light - could also function as a signal to activate vesicular 
glutamate release from nerve terminals and slices.  
It is to be noted that in our experiments the laser light was administered directly on nervous 
tissues, while in clinical conditions laser light should pass through the skull of the subject, 
which is not represented in our experimental model. Although these limitations, we believe 
that these finding can be of interest for the application of low laser intensity on nervous 
system. Nevertheless, it is to be considered that glutamate is a well-known excitatory 
neurotransmitter involved in nociceptive signalling in CNS (Pires de Sousa 2016). 
 
Future directions 
Future studies are required to deepen the topic and to understand the mechanisms 
involved in the low intensity laser ability to enhance glutamate release not from astrocytic 
processes but only from the nerve terminals.   
Preliminary data (data not shown here) suggest that photobiomodulation can evoke not 
only glutamate but also GABA release. Nerve terminals treated with the VGLUT inhibitor 
rose bengal and then stimulated with laser light, could release GABA. It will be of interest 
to compare the effect of photons with the effect of different stimuli, such as depolarization 
or receptor activation, on GABA release. Aa a matter of fact, future experiments will be 
necessary to investigate this phenomenon as well as the effects of photobiomodulation on 




2. Modulation of glutamate release by receptor-receptor interactions in rat striatal 
astrocytic processes 
 
Receptor oligomers have been thoroughly studied since the 80s, when their existence was 
demonstrated in neurons. More recently, they were studied in astrocytic cells and the 
presence of heteromers between A2A and D2 receptors in astrocytic processes was 
demonstrated by prof. Marcoli’s group in previous studies.  
Those findings may be interesting for future therapeutic strategies which target the D2 
receptor: according to our data, indeed, dopaminergic transmission can be modulated by 
allosteric interaction with A2A receptor, also at the level of the astrocytic plasma 
membrane. Therefore, adenosinergic signalling could become relevant in that therapies 
which target D2 receptor, as anti-Parkinsonian or anti-schizophrenic therapies.  
Indeed, our findings indicate that activation of the A2A receptors for adenosine may play a 
crucial role in the regulation of dopaminergic control of the striatal glutamatergic 
transmission through astrocytic receptor-receptor interaction. Evidence for A2A-D2 
heterodimerization may reveal new possible pathogenic mechanisms, therefore new 
possible targets for pharmacological intervention in pathological conditions involving the 
striatal D2 (and A2A) receptors such as schizophrenia as well as the Parkinson’s disease. 
In fact, high D2 receptor activation at the level of striatum or frontal cortex, and reduced 
extracellular adenosine level, have been related to schizophrenia (see Lara and Souza, 
2000). It is interesting to note that the ecto-nucleotidases involved in adenosine production 
from ATP and located near A2A receptors seems abundant in striatal gliosomes (Augusto 
et al., 2013), consistent with important roles of astrocytic A2A receptors in the 
adenosinergic control of striatal glutamate transmission. Furthermore, a dysfunction of the 
glutamatergic transmission is increasingly recognized to be involved in schizophrenia, also 
at the striatal level (Simpson et al., 2010). Evidences for the ability of adenosinergic A2A 
receptor to impair the D2 receptor control of the striatal glutamatergic transmission 
therefore might bring together three major neurochemical actors in schizophrenia, namely 
the dopaminergic, adenosinergic, and glutamatergic transmission. 
As far as the Parkinson’s disease is concerned, we must consider that the D2 receptors 
were found to be modulated not only via A2A receptors, but also by intracellular 
homocysteine. Notably, increased plasma homocysteine levels have been reported in 
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patients affected by Parkinson’s disease, mainly during L-dopa treatment and suggested 
to play a role in dyskinesias during L-dopa treatment (see discussion and references in 
Cervetto et al., 2018); L-dopa has been demonstrated to cause production of 
homocysteine in astrocytes (Huang et al., 2005). It could therefore be hypothesized that 
reduction of homocysteine production (e.g., by COMT inhibitors) together with A2A 
receptor antagonists may play synergistic roles in the therapy of PD against the loss of L-
dopa effectiveness and in the late side effects of L-dopa treatment in Parkinson’s disease. 
Furthermore, we have to remember that activation of astrocytic D2 receptor was reported 
to suppress neuro-inflammation (Shao et al. 2013), while reduced signaling of the 
astrocytic D2 receptors increased the vulnerability of striatal dopaminergic neurons to 
toxic damage. Indeed, changes of striatal astrocytes, and altered interactions between 
astrocytes and neurons at striatal glutamatergic synapses with altered control of 
glutamatergic transmission have been implicated in the pathophysiology of the 
Parkinson’s disease (see Cervetto et al, 2018 and references therein).  
Alltogether these data provide new insights into the involvement of molecular circuits at 
the level of the astrocyte plasma membrane, based on formation of A2A-D2 heteromers, 
in the dopaminergic control of the striatal glutamatergic transmission. These findings on 
the regulation of glutamatergic transmission in striatal astrocyte-neuron communications 
may pave the way to investigations on possible pathogenic mechanisms and to the 
development of new pharmacological approaches to pathological conditions involving 
striatal glutamatergic transmission dysregulation.  
Moreover, we demonstrated that the oxytocin receptor is colocalized with A2A and D2 
receptors in astrocytic processes.  
Data here presented suggest the existence of functional interactions between the OXT and 
A2A receptors in striatal astrocytic processes, while we did not provide evidence for an 
interaction between OXT and D2, even though D2-OXT heterodimers expression has been 
previously described in literature. However, confocal imaging showed that OXT, D2, and 
A2A receptors are co-expressed on the same astrocytic process: it is conceivable that OXT 
receptors can form oligomeric structures with the A2A and, maybe, D2 receptor. 
Further experiments via PLA or co-immunoprecipitation will provide new information on 
biochemical or physical interactions between these receptors. 
As previously mentioned, oxytocin is an important regulator of sexual and social behaviour 
of individuals and its use in therapies against schizophrenia and autism was suggested 
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(Yamasue 2018; Shilling 2016). Interestingly, elevated levels of glutamate were found in 
basal ganglia of patients affected by schizophrenia (Uno, 2019).  
Thus, the fact that oxytocin signal transmission might be affected by allosteric interaction 
with A2A receptors should be kept in consideration for the development of therapies 
targeting oxytocin receptors.  
Interestingly, elevated levels of glutamate were found in basal ganglia of patients affected 
by schizophrenia (Uno, 2019).  
According to our data, the pathways leading to glutamate release in astrocytic processes 
are controlled both by the dopamine and Oxytocin receptors, with functional interactions 
with the adenosine A2A receptor.   
If the expression of the A2A-D2-OXT receptor heteromers in astrocityc processes will be 
confirmed in the future, a new perspective for the treatment and the development of new 
drug for diseases or psychiatric disorders would be opened.  
 
Future directions  
 
The topic of receptor-receptor interaction at the level of the plasma membrane of 
astrocytes is only at the beginning and requires further work for a better understanding of 
the modes for the interaction between or among different GPCRs, the functional effects of 
the interactions, and the regional selectivity. In any case, these findings open a new field 
of investigation, on possible roles for astrocytic receptor-receptor interaction in the 
astrocyte signalling and in the control of the glutamatergic transmission. Furthermore, 
evidence for receptor-receptor interaction highlights the roles that astrocytes may play in 
the decoding of signalling in central nervous system. Altogether, the findings may 
contribute to the change from a neurocentric to a neuro-astrocentric view of the brain 





3. Exosomes release from astrocytic processes 
 
Exosomes extrusion from astrocytic processes can be intended as a volume transmission 
mode of communication (Agnati and Fuxe, 2000; Vizi, 2000), with a non-classical typology 
of release.  
Exosomes are known to play an important role in communication between CNS cells, 
carrying molecules (e.g: proteins or mi-RNA) and messages which can have both protective 
or enhance harmful processes.  
Thus, these new findings are relevant in defining the role of astrocytes in CNS not only as 
cells involved in supporting neurons functions but also able to participate in CNS 
communication in multiple ways, through the release of glutamate (classical mode of 
transmission) or exosomes (non-classical mode of volume transmission, the roamer-type 
volume transmission).  
In particular, in the context of the putative roles that exosomes might play under 
physiological or pathological conditions in the CNS, the results here reported appear 
relevant since:  
- they demonstrate that astrocytic processes can release exosomes. Signal transmission in 
gliosomes can occur through either vesicular release of gliotransmitters or roamer-type 
pattern as in case of exosomes. These evidences contribute to elucidate the multiple roles 
that astrocytic processes may play in the control of signal transmission in CNS. 
- shed a new light on exosomes origin. The fact that these nanovesicles express astrocytic 
markers allows the identification of the cellular origin of exosomes which can be collected 
from different biological fluids. The involvement of a precise cell population in a 
physiological or pathological process could thus be established, helping to define the 
potential role of peripheral exosomes in the pathogenesis, diagnosis, and monitoring of 
various CNS pathologies.  
- According to our data, exosomes carry the protein NGB. Although NGB was thought to be 
expressed only in neurons, its expression in astrocytes was observed. The hypothesis 
advanced is that NGB may play a role in neuroprotection for neurons. In that case, 
exosomes release from astrocytes might have a protective role transferring the NGB 
protein to neurons through the release of vesicles.  
To further investigate this aspect, we added labelled exosomes to astrocyte-neurons co-
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culture to figure out whether astrocyte-derived nanovesicles can be up-taken by neuronal 
cells, our confocal imaging showed that exosomes are actually able to target and enter in 
neuronal cell.  
 
Future directions  
 
In conclusion, we can state that astrocytic processes can release NGB+ exosomes which 
selectively target neurons.  
Future studies will establish whether NGB - or any other signal is contained in exosomes -
is transferred from astrocytic-derived exosomes to neurons and if, in case, neuronal cells 




ERASMSUS+ PERIOD-BRIEF ACTIVITY DESCRIPTION 
 
During my PhD, I spent six months (from the 1st of July to the 31st of December 2019) in 
Düsseldorf (Germany) in prof. Ellen Fritsche’s lab at IUF-Leibniz Research Institute for 
Environmental Medicine.  
The aim of the period was acquiring the experience in managing induced pluripotent stem 
cells (iPSCs), using different protocols aimed to obtain adult neurons and astrocyte from 
progenitors cells.  
Results were presented in the following abstract, presented at the 11th 11th World 
Congress on Alternatives and Animal Use in the Life Sciences (WC11):  
 
Hartmann J, Pelassa S, Pahl M, Klose J, Tigges J and Fritsche E.  
2D Neural Inductions of Human Induced Pluripotent Stem Cells (hiPSCs) followed by 3D 
Differentiation as Alternative Method for (Developmental) Neurotoxicity Testing 
  
 Here, I briefly describe the role of iPS cells in scientific research and the preliminary results 
obtained during my time in Düsseldorf.  
Human induced pluripotent stem cells (h-IPSCs) were generated for the first time in 2006 
by the Japanese scientist Shin’ya Yamanaka, who was awarded with the Nobel Prize in 2012 
(shared with Jonh B. Gurdon).  
h-IPSCs represent a milestone in scientific research, since differentiated cells can be 
converted into pluripotent stem cells which can be pushed to differentiate towards 
potentially all phenotypes, opening wide perspective on their use in research and clinical 
therapies.  
Yamanaka obtained ES-like cells through retrovirally introduction of four transcription 
factors in mice fibroblasts: Oct3/4, Sox2, Klf4 and c-Myc (Takahashi et al., 2006).  
However, results were unsatisfying: ES marker were lower expressed in h-IPSCs than in ES 
and h-iPS were not able to generate adult chimera.  
Other groups obtained IPS cells with a ES-like DNA methylation pattern, even though highly 
subjected to tumour development due to transgene c-Myc reactivation  
This issue was solved by Nakagawa and Koyanagi who managed to generate iPSC excluding 




h-IPSCs can be differentiated in vitro into different fates and thus represent a major tool 
for biomedical research and personalized medicine, since cells can be obtained from 
patients.  
Nowadays, iPSCs are currently used for modelling neurodegenerative diseases (Parkinson’s 
and Alzheimer’s disease), and psychiatric disorders as schizophrenia (Wu,2018) or 
personalized medicine (Li et al.,2016).  
H-IPSC, indeed, enable scientists to obtain human cells not derived from embryos, thus 
avoiding the bioethical concerns connected with those practices.  
Although animal models played a fundamental role for the development of scientific 
knowledge, nowadays the role of induced pluripotent stem cells is being increasingly 
recognized.   
Our laboratory has been working on animal models (in particular mice and rats) for a long 
time, as witnessed by publications in peer-reviewed journals (Cervetto et al., 2017; 
Venturini et al, 2019; Pelassa et al., 2019 and references therein). However, we believe that 
h-IPSC could provide a new useful model both under the scientific and the ethical profile. 
For this reason, through the Erasmus+ program, I had the opportunity to spend six-months 
at IUF.  
From July to December 2019, then, I participated to prof. Fritsche’s lab activity.  
In particular, the aim of my research was understanding the efficacy of the Monolayer 
Culture Neural Induction Protocol from StemCell Technologies in inducing IPS 
differentiation towards the astrocytic and neuronal phenotype.  
The parameters used to asses h-ipsc differentiation in astrocytes or neurons were: 
- marker expression  
- electrical activity   
 
1. Marker expression  
 
Mature phenotype can be observed 28 days after the induction of the protocols. 
However, RT-PCR analysis showed that the 99% and 95% of cells resulted positive, 
respectively, for PAX-6 and Nestin, (neuroprogenitors makers), 7 days after neural 
induction.  
The expression of pluripotency marker Oct 3/4 was measured only in the 2,74% of cells. 
Even though PAX6 expression decreases during the time, Nestin and OCT3/4 expressions 
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remained constant, suggesting that IPS cells were effectively differentiated in Neural 
Progenitor Cells (NPCs).  
 
 
Figure.15 Representative immunohistochemical imagines on IPSC-derived and astrocytes 
Cells were positive for the astrocytic markers S100β (green, left image) and GFAP.  
Mature neurons marker expression was evaluated after culturing NPCs in a differentiation medium for 28 
days. Neuronal marker MAP2 and BIII or astrocytic marker S100β and GFAP were used to understand whether 
NPCs obtained from the Monolayer protocol differentiated in mature neurons and astrocytes.As shown by 
the images, it seems that the Monolayer Protocol affectively enhance iPSCs differentiation in mature neurons 
and astrocytes.  
 
2. Electrical activity of Monolayer protocol-derived cells 
 
Since neurons in physiologic conditions are able to set up electrically active network, in 
vitro cells aimed to mimic neuronal cells are supposed to do the same.  
According to the preliminary result obtained, it seems however that neurons differentiated 
from the monolayer protocol do not show any electrical activity. However, this is a very 
preliminary results and further investigation is requested for a better understanding of the 










Fig.16 Microelectrode Array alysis on mature cells differentiated from iPCs following the NIM 
protocol 





Although prof. Marcoli’s group has a long and well documented background with animal 
models, our interest is also addressed to the in vitro cutting-edge techniques which can 
play a key role in modelling human physiologic or pathological conditions.   
Therefore, the most important aim of my Erasmus period was acquiring the technical skills 
necessary for iPSC culturing.  
The results here presented, even though partial and preliminary, show that the goal was 
achieved. 
Handling iPSCs culture open new future perspectives to the future activities of our group. 
Interesting collaborations and projects involving the use of induced pluripotent stem cells, 
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